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PREFACE 
The main part of this thesis consists, firstly, 
of a series of papers illustrating the development of 
the writer's quantitative approach to the study of the 
action of histamine antagonists in man; and, secondly, 
of a note concerning trials of antihistaminics, 
followed by the description of a pilot trial of one of 
these drugs. Some repetition has been unavoidable in 
the published accounts. 
The supporting part of the thesis consists of two 
papers, in order of their publication. The first 
describes some early work on the mode of action of 
autonomic nerves, and is followed by a short addendum. 
The second, and more important contribution, deals 
with the inactivation of adrenaline - thought, at that 
time, to be the transmitter of adrenergic nerve 
effects. It is followed by a short addendum 
extending some of the observations to various mammals, 
including man. The war interrupted this work, but it 
was resumed, and extended to include noradrenaline, 
when that substance became available. A second 
addendum summarises some of the more recent observa- 
tions. 
This work, on histamine antagonists and on 
adrenaline and noradrenaline, is being continued. 
Some of the methods developed in it are being success- 
fully applied to related fields, both by the writer 
and by some of his pupils. 
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PHYSICLAN REGISTRAR 
DERMATOLOGICAL DEPARTMENT, GENERAL INFIRMARY AT 
LEEDS 
Tam reaction to an intradermal injection of histamine 
is modified if the injection is repeated at an interval 
after the oral administration of an adequate dose of 
a histamine antagonist. (Warembourg et al. 1944, 
Friedlaender and Feinberg 1946, Halpern et al. 1946a and 
b, Leavitt and Code 1947.) We present here the results 
of some preliminary observations in which the modifica- 
tion of the intradermal histamine reaction has been 
used to study the variation in effective dosage, duration 
of action, and other properties of various anti -histamine 
agents : 2- dimethylaminoethyl benzhydryl ether hydro- 
chloride, introduced by Loew et al. (1945) and marketed 
as ` Benadryl ' (Parke Davis) ; N(2-dimethylamino- 
ethyl) N(p-methoxybenzyl) 2- aminopyridine, intro- 
duced by Bovet and Walthert (1944) as ` 2786 R.P.,' 
known in France and the U.S.A. as ` Neoantergan,' 
and now obtainable in this country under the name of 
` Anthisan ' (May & Baker) ; and N(dimethylamino- 
2-propyl) phenothiazine, first described by Halpern et al. 
(1946a and b) and known as ` 3277 R.P.' Administration 
of equal quantities of the different drugs was precluded 
by the wide differences in the ratio between the thera- 
peutic and the toxic doses ; ordinary clinical doses 
were therefore used. 
The histamine reactions were produced on the volar 
surface of the forearm by the intradermal injection 
of 0.05 ml. of a solution of histamine acid phosphate 
0.01% w/v in saline solution. Each injection thus 
contained 5.0 pg. of the acid phosphate, equivalent to 
1.81 µg, of histamine base. 
Whereas the flare component of the histamine response is 
clearly an area, the weal is three -dimensional and would 
be properly measured as a volume ; but it was not found 
feasible to do this, and so both flares and weals were treated 
as areas. These can be determined by inking the outlines of 
the reactions on the skin, transcribing them to thin tracing- 
paper, and computing directly. With the dose of histamine 
- used, however, the reactions were such that the areas as 
directly determined were virtually identical with those 
calculated from the mean radius of each reaction; as obtained 
from the average of two diameters, measured at right angles, 
in each instance. The labour involved in measuring the 
diameters was much less than in computing areas directly ; 
so all the measurements on patients were made in this way, 
the average diameters of the weal and of the flare being 
determined 5 -10 min. after the injection of each dose of 
histamine. It is these measurements which are given in 
t ables I -Iv and figs. 4-9, but in figs. 1 -3 the areas 
calculated from these diameters are used. All the injections 
and measurements on patients were carried out by the same 
observer (R. P. W.). 
In eleven men intradermal histamine reactions were 
measured before, and at intervals after, a single dose of 
benadryl 100 mg. by mouth. After a week's rest the 
observations were repeated with anthisan 200 mg. 
and, after a further week, with 3277 R.P. 50 mg. Other 
observations were made on twenty patients with chronic 
urticaria in whom the effect of anthisan on the modifica- 
tion of the intradermal histamine reaction and of the 
urticaria was compared. 
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RESULTS 
Modification of Normal Histamine Reaction by Single 
Doses of Histamine Antagonists 
Tables I -III give the results of these observations, 
together with their means, the differences in the means 
(m1 -m2), and the standard errors of the means (Em) 
and of their differences (Ed) calculated in the ordinary 
way. The paired t -test (Fisher 1944) has been applied 
to the estimate of t given in the lowest row of the tables. 
A diagrammatic representation of the mean results is 
given in fig. 1. 
Judged from the mean maximal reduction of both 
weals and flares, the effects of anthisan 200 mg. and of 
3277 R.P. 50 mg. were considerable and did not differ 
significantly, but the effects of benadryl 100 mg. were 
barely significant, and in the weal response alone, at 
three hours. 
The differences in duration of action of each of the three 
drugs are also shown. Thus, though there was only a 
questionably significant reduction of the weal response 
3 hours after administration of benadryl 100 mg., the 
effect of anthisan 200 mg. was still significant, both in 
weal and flare responses, at 27 hours, and of 3277 R.P. 
50 mg. at 32 hours. 
The frequency of our observations was not sufficient 
to enable us to get accurate information about any 
differences in the rate of establishment of the effect 
with each of the drugs, but it seems that anthisan and 
3277 R.P. have some effect within an hour, and that the 
maximal effect is likely to be reached in 3-4 hours. The 
maximal effect persists longest with 3277 R.P. 
TABLE I- EFFECTS OF SINGLE DOSES OF BENADRYL 100 MG. BY 




Average diameters after benadryl (cm.) 
Subject (cm.) 1 hour 3 hours 10 hours 
Flares Weals Flares Weals Flares Weals Flares Weals 
A 3.1 1.25 2.1 1.1 2.4 1.05 2.7 1.15 
B 2.6 1.15 2.4 1.2 2.1 1.1 2.4 1.15 
C 3.1 1.3 2.0 1.2 2.1 1.1 2.4 1.15 
D 3.7 1.3 3.9 1.25 4.3 1.3 4.6 1.3 
E 3.6 1.2 3.6 1.25 3.1 1.2 3.6 1.2 
F 3.6 1.4 3.6 1.25 4.1 1.25 4.6 1.25 
G 4.1 1.3 3.1 1.1 3.6 1.2 4.6 1.25 
H 3.6 1.2 3.8 1.25 4.0 1.25 4.7 1.25 
I 4.3 1.25 4.6 1.3 4.1 1.2 3.9 1.3 
J 4.0 1.2 4.1 1.1 3.8 1.1 4.1 1.1 
K 3.6 1.2 3.8 1.15 3.4 1.2 3.8 1.25 
Mein 3.57 1.25 3.36 1.19 3.36 1.18 3.76 1.21 
m, -m2 . . .. -0.21 -0.06 -0.21 -0.07 +0.19 -0.03 
Em 0.147 0.024 0.259 0.027 0.250 0.024 0.268 0.024 
Ed .. 0.298 0.036 0.290 0.034 0.305 0.034 
G .. 1.18 1.82 1.24 2.04 0.97 1.53 
TABLE II- EN.rECTS OF SINGLE DOSES OF ANTHISAN 200 MG. BY MOUTH ON INTRADEEMAL HISTAMINE REACTION 
diameters Average 
(cmm .) before anthisan Average diameters after anthisan (cm.) 
Subject 2 hours 4 hours 11 hours 27 hours 
Flares Weals 
Flares Weals Flares Weals Flares Weals Flares Weals 
A 3.5 1.3 3.5 1.3 1.0 0.5 2.0 0.6 2.0 1.0 
B 3.0 1.3 2.5 1.3 1.0 0.6 1.5 0.6 1.5 0.9 
C 3.0 1.3 2.5 1.0 1.0 0.5 1.4 0.6 1.5 1.0 
D 3.6 1.3 2.5 0.75 2.4 0.7 3.5 0.6 3.5 1.0 
E 3.5 1.0 1.5 0.55 1.0 0.5 1.8 0.6 3.0 0.9 
F 3.5 1.6 3.0 0.8 2.5 0.7 2.5 0.8 3.5 1.05 
G 4.0 1.3 2.5 1.0 1.0 0.5 2.0 0.55 3.0 1.05 
H 4.5 1.2 3.5 1.2 1.5 0.6 2.9 1.0 4.0 1.2 
I 4.5 1.2 3.5 1.1 2.7 1.1 2.5 0.8 3.5 1.0 
J 3.8 1.2 3.5 1.0 2.0 0.55 2.8 0S 4.0 1.0 
K 3.1 1.0 2.0 0.8 2.0 0.6 2.1 0.8 3.0 0.8 
Mean 3.63 1.25 2.77 0.98 1.63 0.62 2.27 0.70 2.91 0.99 
un, -m2 .. . . -0.86 -0.27 -2.00 -0.63 -1.36 -0.55 -0.71 -0.26 
Em 0.160 0.051 0.206 0.069 0.208 0.054 0.19 0.042 0.274 0.033 
Ld .. 0.261 0.086 0.262 0.074 0.248 0.066 0.317 0-061 
t .. . . 2.66 2.38 3.01 3.02 2.94 3.98 2.47 2.83 
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TABLE III -EFFECTS OF SINGLE DOSES OF 3277 R.P. 50 MG. BY MOUTH ON INTRADERMAL HISTAMINE REACTION 
Subject 
Average diameter 
before 3277 R.P. 
(cm.) 
Flares Weals 
A 3.0 1.3 
B 3.4 1.3 
o 2.6 1-35 
D 3.4 1.15 
E 3.9 11 
F 3.6 11 
G 4-2 1.4 
H 4.5 1.4 I 3-2 1.1 
J 40 1.0 
K 4.2 12 
Mean 3-64 1.25 
rai-m, 
Em 0.175 0.042 
Ed 
t 
Average diameter after 3277 R.P. (cm.) 
1 hour 3' /, hours 7'/a hóurs 24 hours 32 hours 
Flares Weals Flares Weals Flares Weals Flares Weals Flares Weals 
1.8 0.95. 1.5 0.8 1.2 075 11 065 
1.4 1.0 1.6 0.7 1.0 075 1.0 0-85 
1-6 0.95 1.1 07 1-2 0-7 1.4 0.7 
21 0-85 2.4 0.75 1.8 0.85 3.6 0.95 
1-65 0-95 0.15 0.7 1.1 0.65 1.4 0.7 
3.2 095 2-4 0-9 2-2 07 2.6 01 
2.9 0.85 0.9 0.75 1-7 0.7 1.6 0.8 
3.7 1.0 2.1 0.9 21 01 3-2 1.1 
3.4 01 1-9 0.8 2-2 0-65 21 01 
2.2 0.8 1-5 0.6 1.7 0-6 3.2 01 
1.6 075 1.1 055 1.4 0.85 17 1.2 
2.32 090 1.63 0.74 1.61 0.74 2-16 0.88 
-132 -035 -2.01 -0.51 -2.03 -0.51 -148 -0.37 
0.247 0-024 0.154 0.036 0.138 0136 0.283 0.048 
0.303 0.087 0.233 0-055 0-223 0-055 0.333 0064 

















Variation in Response to Histamine Antagonists 
The response of different people to the anti -histamine 
drugs varied in the degree of maximal reduction of the 
erythema and wealing. When the maximal response of a ' 
person was poor with one of the drugs it was usually 
poor with the others also. Of the eleven persons studied, 
the degree of response in five (A, B, C, E, and G) was 
good ; in three (D, F, and I) poor ; and in the remaining 
three (H, J, and S) intermediate. Examples of good and 
poor responses taken from tables I -III are shown in fig. 2. 
This variation in response did not seem to depend on 
the extent of the initial reaction to intradermal histamine ; 
nor was there any obvious correlation between the degree 
of specific response to the drugs, the toxic side -effects, 
and the weight or build of the person. 
It would be expected, on general pharmacological 
grounds, that people who responded poorly tó an ordinary 
dose of an anti -histamine drug would respond well if 
the dose were raised sufficiently. This was found to be 
so, and is demonstrated in fig. 3, where the effect of 
raising the dose in subjects D, I, and J is shown. 
Apart from the differences already noted respecting the 
mean duration of action of each of the different anti- 
histamine drugs there is considerable variation from one 
person to another in this respect. But, as with the 
maximal effects, a person who showed a long duration of 
action with one of the agents showed, in most instances, 
a long duration of action with the other two. This is 
illustrated in subjects A, B, C, E, and G, all of whom 
showed a good maximal response (tables I -m), and it 
suggests a close correlation between these two aspects 
of the action. 
Side - effects of Histamine Antagonists 
In comparing the clinical value of anti -histamine 
drugs an important consideration is the ratio between 
the therapeutically effective dose and that which gives 
rise to side -effects. The assessment of the incidence 
and importance of the various side -effects is, however, 
complicated. The commonest symptoms are drowsiness 
and lassitude, and the reaction to these depends consider- 
ably on the sensitivity and type of the patient. Again, 
toxic symptoms are more common in ambulant persons 
than in those resting in bed. Thus seven ambulant 
medical workers on a single dose of anthisan 200 mg. 
all experienced mild symptoms, whereas of eleven men 
resting in bed on the same dose only one complained 
of a little drowsiness. When large clinical doses of the 
drugs were given, nearly all patients complained of some 
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Fig. I- Modification of intradermal histamine reaction by single doses 
of anti -histamine drugs (mean results from eleven people) : stippled 
area I' /s times area of flares ; hatched areas 4 times area of weals. 
with low doses in a few people, and in some people 
have been pronounced before an effective anti -histamine 
dosage could be reached. 
Of our eleven subjects benadryl 100 mg. caused 
drowsiness and lassitude in four, anthisan 200 mg. in 
one, and 3277 R.P. 50 mg. in five. The results in this 
small series are in accord with observations on other 
people, though experience with 3277 R.P. has been 
limited. Anthisan certainly has a considerably higher 
therapeutic ratio than has benadryl, but we have 
insufficient information to reach any definite conclusion 
about 3277 R.P. in this respect. Vallery -Radot et al. 
(1947), however, agree that side -effects are commonly 
experienced with 3277 R.?., but state that, when the 
therapy is continued for a few days, they tend to 
pass off. 
Dryness of the mouth has been noted with benadryl 
and 3277 R.P. but was commoner with anthisan, develop- 
ing in about 20% of patients on an average dose. It 
was noted about 2 hours after ingestion of the drug 
and lasted 11/2-2 hours but did not cause serious dis- 
comfort or complaint. Average doses of anthisan in 
some patients caused mild colic, diarrhoea, nausea, and 
vomiting, which began about 11 /2 hours after ingestion 
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SUBJECT A SUBJECT B SUBJECT D SUBJECT F 
( GOOD ( GOOD (POOR ( POOR 
RESPONSE) RESPONSE) RESPONSE) RESPONSE) 
Fig. 2- Modification of intradermal histamine reaction by single doses 
of anti -histamine drugs in different people (A, B, D, and F) : a, before 
administration of anti- histamine drug ; 6, after benadryl 100 mg. ; 
c, after anthisan 200 mg. ; d, after 3277 R.P. 50 mg. ; stippled and 
hatched areas as in fig. I. 
4 
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And cleared after I -11/$ hours. Since the precaution 
of administering the drug in the middle of meals was 
introduced we have had very little trouble from these 
effects. 
Light -headedness, aching limbs, and ataxia have been 
experienced with 3277 Bd'. 
Observations on Patients with Chronic Urticaria 
Similar observations to the foregoing have been 
carried out on twenty patients with chronic urticaria, 
the intradermal histamine reactions being noted at 
various times before, during, and after treatment with 
anthisan. 
The weals were suppressed or considerably modified 
in all patients. Variation from one person to another 
in the response to the anti -histamine drug was shown 
as in the foregoing observations, and in three patients 
who required large doses of anthisan the side -effects 
outweighed the value of continuing the suppressive 
therapy. 
In all cases the dosage necessary to reduce adequately, 
or to suppress, the urticaria was that necessary to modify 





Fig. 3- Effect of increasing dose of anti -histamine drug in different 
people (D, I, and J) giving poor response to ordinary dose: o, before 
administration of anthisan ; 6, after anthisan 300 mg. daily for three 
days ; c, after anthisan 600 mg. daily for three days ; d, after anthisan 
900 mg. daily for three days ; stippled and hatched areas as in fig. I. 
Five of the patients had various degrees of factitious 
wealing. Measurements of the size of the weal and 
erythema provoked by different stimuli were made 
before, during, and after therapy. The stimuli used 
were weak and firm pressure with the stroke of a pin- 
point, and weak and firm pressure with the end of a 
cylindrical stick 2 mm. in diameter. The degree of 
reduction of weal and erythema by anthisan paralleled 
the reduction of the intradermal histamine reaction. 
When the drug was stopped, urticaria recurred in most 
patients ; two complained that it was more severe than 
before treatment, but in these, as in the others, the 
intradermal histamine reaction was about the same as 
before therapy. In the five patients who showed 
factitious wealing the measurements of the weal and 
erythema, when the drug was stopped, were about the 
same as they were before therapy. 
The action of anthisan in these patients followed in 
all respects the course to be expected from the results 
of the observations recorded above. Various points are 
illustrated by examples from the ease -records. Figs. 4-8 
illustrate variation of the effective dose of anthisan from 
one person to another. Tho following are examples of 
variation of duration of action of anthisan from one person 
to another. 
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Key to figs. 4 -9 : (I) toxic symptoms : +, slight symptoms on question- 
ing ; + +, complaint of mild symptoms ; + +-I-, complaint of moder- 
ate symptoms ; + + + +, severe incapacitating symptoms ; (2) 
urticaria : +, occasional weal ; + +, a few weals ; -1- + +, moderate 
number of weals ; + + + +, profuse weals. 
Intradermal histamine reaction from 0.05 ml. of 0.01 % histamine acid 
phosphate. Mean diameters of flare (thin line) and weal (thick line) 





Intradermal histamine reaction 
(cm.) 
Urticaria 
Nil - + -I- + 1 11111 
100 I 
+ 100 Nil 
100 i 
200 
200 + -III.-- Nil 
200 
Nil - + + + 
I I 1 I I 
0 05 1 152 
Fig. 4- Average effective dose of anthisan in a man, aged 69, weight 
78 kg., with urticaria present for 3 months. 
Short Duration. -In a woman, aged 38, weight 50.5 kg., 
with urticaria present for 6 months, the intradermal histamine 
reaction was modified by anthisan 200 mg. t.d.s. Coincidentally 
the urticaria was suppressed during the day but reappeared 
about 2 A.M. (the doses of anthisan were given at 7 A.M., 
1 P.M., and 6 P.M.). Thus, in this patient 
an effective level of anthisan was main- 
tained for only 8 hours after ingestion. 
A further dose at 1l P.M. relieved this 
early morning urticaria. 
Long Duration. -In a woman, aged 23, 
weight 63.5 kg., with urticaria present 
for 4 months, who provided an example 
of a low effective dose (fig. 7), anthisan 
100 mg. modified the intradermal hista- 
mine reaction, and, given as a single dose 
at 8 A.M., suppressed the urticaria for 24 
hours. If anthisan was discontinued, 
urticaria reappeared only 36 hours after 
the last dose. The intradermal histamine 
reaction remained modified 24 hours after 
the dose. 
An example of side -effects associated 
with a low effective dose is given in 
fig. 9. Drowsiness and lassitude were 
too severe for the patient to derive benefit from continued 
therapy. On the other hand, in a case cited as providing 
an example of a high effective dose of anthisan (fig. 5) 
toxic symptoms were not experienced until a dosage of 
1200 mg. in 24 hours had been reached. Even then the 
symptoms were so mild that therapy was continued. 
Anthisan 
(mg.in24hr.)symptoms 
Toxic Intradermal histamine reaction 
(cm.) Urticaria 
Nil - + + 
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Fig. 5 -High effective dose in a woman, aged 49, weight 55.5 kg., with urticaria present for 2'¡s years. 
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Fig. 6 -High effective dose in a man, aged 23, weight 65 kg., with urticaria present for 
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Fig. 7 -Low effective dose in a woman, aged 23, weight 63.5 kg., with 
urticaria present for 4 months. 
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(mg .in24 hr) 
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Fig. 8 -Low effective dose in a woman, aged 20, weight 64 kg., with urticaria present for 
2 years associated with dermographism. 
Anthisan 
(mg. in 24 hr.) 
Toxic 
symptoms 
Intradermal histamine reaction 
(cm.) Urticaria 
Nil - + + 
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Fig. 9 -Low effective dose associated with side- effects in a woman, aged 




The intradermal histamine response shows clearly 
that there are well- marked differences not only in 
potency but also in the mean duration of action of 
the different anti -histamine drugs. Benadryl is short - 
acting, anthisan and 3277 R.P. are long -acting, and 
the action of 3277 R.P. lasts longer than that of anthisan. 
This factor of duration öf action for a single dose merits 
more attention than it has received in the clinical assess- 
ment of anti -histamine drugs. Indeed, next to the 
therapeutic ratio it may be the most important feature 
in any new drug of this class. 
The question immediately arises what mechanisms 
determine duration of action in the different drugs I 
Are the anti -histamine drugs, for example, analogous to 
the long - acting and the short -acting barbiturates, where 
duration of action depends simply on the rate of break- 
down by the liver, or excretion by the kidneys, or both ? 
From preliminary experiments made by one of us 
(W. A. B.) in collaboration with P. B. Dews, it seems 
that the explanation is not so simple, and that one of the 
main factors may be variation in the degree and duration 
of fixation of the different drugs by the tissues on which 
they act. The subjects of these observations were medical 
students of either sex: In the first experiment it was 
intended to show the relative potencies of the three 
drugs by local administration to the skin. Each of 
thirty people had four intradermal injections, one of 
which contained 10 µg. of histamine base as control, 
and each of the others 10 µg. of histamine plus 100 pg. 
of the anti -histamine drug. The area of each weal was 
outlined in ink 5-10 min. after the injection, and the 
area determinéd from a tracing of the weal outline. 
Flares were disregarded because of the known local 
anmsthetic properties of the drugs. For convenience of 
presentation the results are expressed for each drug as 
the mean percentage reductions of the weal area below 
that of the control. The effects of simultaneous adminis- 
tration of histamine and the three anti -histamine drugs 
are shown in the first row of table iv. Benadryl and 
anthisan both gave significant reductions in the response, 
but, very surprisingly, 3277 R.P. did not. 
TABLE IV- ACTIONS OF ANTI- HISTAMINE DRUGS ADMINISTERED 









Mean % reduction in area of weal response, 
± standard error of mean 
(min.) Benadryl Anthisan 3277 R.P. 
0 30 25 -5 ± 5.7 32.6 ± 5.8 9.9 ± 7.3 
10 10 24.3±8.0 46.6±6.3 46.6±9.1 
30 10 16.8 ±8.4 33.1 ±6.0 41.1 ±5.6 
100 10 7.7±12.2 26.8±7.9 43.3±5.2 
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In view of these results we made further observations, 
in which areas of the skin were infiltrated with the anti- 
histamine drugs (0.2 ml. of 0.1 % w /v) and the histamine 
was injected in different groups of people at different 
intervals thereafter. The control injection of histamine 
was made to an area of skin infiltrated with saline solution. 
The anti -histamine drugs in the concentration used caused 
a characteristic red reaction. The limits of the reaction 
were readily visible, and the subsequent histamine 
injection was given into this area. The results are 
given in the second and subsequent rows of table iv. 
The effect of benadryl was maximal at zero time 
(complete immediate fixation with maximal exclusion 
of histamine), began to pass off almost immediately, and 
was only questionably significant at 30 min. (light and 
short -lasting fixation). With anthisan the effect at 
zero time was not maximal (incomplete immediate 
fixation) but became so in a few 
minutes ; there was still a signi- 
ficant effect at 100 min. (firm and 
lasting fixation). With 3277 R.P. 
there was no significant effect at 
zero time (slight immediate fixation), 
but the effect was maximal by 
10-15 min. and was still at this 
level at 100 min. (firm and lasting 
fixation). In some subsequent obser- 
vations on other subjects, but using 
a 1.6 µg. test dose of histamine, 
significant effects have persisted 
with anthisan to about 1000 min. and with 3277 R.P. 
to 3000 min. The standard errors of the observations 
in table iv give some idea of the variation from one 
person to another in both degree and duration of effect 
with the different anti -histamine drugs when administered 
locally to the skin. 
It is thus evident that the differences in duration of 
action of the three anti- histamine drugs given by mouth 
have features analogous to those shown after their local 
application to tissues. It cannot therefore be supposed 
that the different durations of action observed clinically 
are due simply to differences in the rate of excretion or 
detoxication of the drugs, but are probably due, in part 
at least, to differences in the " firmness of fixation " 
of each drug by the tissues. 
Besides these differences in the duration of action 
characteristic of each of the anti -histamine drugs, it 
was to be expected that there would be considerable 
variation from one person to another in the response 
to the drugs as indicated by the intradermal histamine 
reaction or by the modification of an urticaria. This 
is amply shown by our results, as is the further point 
that the response in any person is comparable for all 
three drugs, with the result that a person who is, 
for example, resistant to anthisan is also resistant to 
3277 R.P. 
It was to be expected, however, again on general 
grounds, that in people resistant to any anti -histamine 
drug (and in whom therefore the response to a given 
dose was less in degree and duration than the mean 
response), the degree and duration of the response could 
be made to approximate to the mean response for the 
particular drug by a suitable increase of the dose. This, 
in fact, is what happens. Thus, whereas the ,average 
daily dose of anthisan is 300 mg., people resistant to it 
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and those who show a small and short response to such 
a dose, may give an adequate response after 600, 900, 
or even 1200 mg. in 24 hours. On the other hand, 
though in our 20 patients treatment with anthisan 
suppressed or considerably modified the urticaria in 
all, in three of these who were resistant to the drug, 
and to whom therefore large doses had to be administered, 
therapy was discontinued because toxic symptoms 
outweighed the value of suppressing the urticaria. 
Therefore, though adequate anti -histamine effects can 
be obtained with the present anti -histamine drugs, 
in resistant people by a suitable increase of dose, the 
toxic effects which may derive from such a dosage are 
an important limiting factor in their usefulness. 
In some people who are only moderately resistant 
to these anti -histamine drugs adequate clinical effects 
may be obtained with normal dosage during the day ; 
but, the duration of effective action being shorter than 
normal, a subeffective level is reached between the last 
dose on one day and the first on the next. Three of our 
patients on anthisan t.d.s. had recurrences of the 
urticaria in the early hours of the morning, some 8 -12 
hours after the last dose. This was completely controlled 
by giving an extra dose, with a little food, last thing at 
night. 
Nearly all the reports published on the clinical use 
of anti -histamine drugs in chronic urticaria have shown 
that some patients were not improved. This number 
has varied from one worker to another as follows 
No. of cases No. not 
Reference Drug treated improved 
Frledlaender and Feinberg (1946) Benadryl 14 .. 4 
Friediaender(1946) .. .. Benadryl 11 .. 2 
Goldberg (1946) .. .. .. Benadryl 15 3 
Shaffer et al. (1945) .. Benadryl 8 .. 1 
O'Leary and Farber (1947) .. Benadryl 75 .. 10 
McGavack et al. (1947) .. .. Benadryl 36 .. 3 
Curtis and Owens (1945) .. Benadryl 17 .. 4 
Levin (1946) .. .. .. Benadryl 9 .. 3 
Waldhott (1946) .. Benadryl 20 .. 4 
Osborne et al. (1947) .. ..Pyribenzamine 15 .. 6 
Arbesman et al. (1946) .. ..Pyribenzamine 107 .. 23 
American Academy of Allergy 
(1946) .. .. ..Pyribenzamine 97 .. 21 
Britton (1947) .. .. .. Antistin 11 .. 6 
Hunter (1947) .. .. .. Anthisan 8 
Vallery -Radot et al. (17) .. 3277 R.P. 47 .. 1 
Total .. .. .. 490 .. 91 
On the basis of our observations it is difficult to 
escape the conclusion that many of these failures were in 
people resistant to the drug, and that, if the dose had been 
suitably increased or a change made to a more powerful 
drug, the response in these people would have been 
satisfactory, as it was in our cases. In any event it is 
probable that, in previous work on anti -histamine 
drugs, even where attention was paid to differences in the 
potency and duration of action of the different drugs, 
there was little appreciation of the variation in response 
from one person to another to any one of them. It is 
clear, however, that this variation is important, and the 
methods described here are readily applicable to its 
assessment for clinical purposes. 
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sUMMARY 
The quantitative modification of the - intradermal 
histamine reaction by the oral administration of the anti- 
histamine drugs ' Benadryl,' ' Anthisan' (' Neoantergan '), 
and 3277 R.P. is described. 
These drugs differ in their weight- for -weight effective- 
ness and in their duration of action, benadryl being 
classed as relatively weak and short -acting, and anthisan 
and 3277 R.P. as potent and long- acting. 
There was considerable variation from one person to 
another in the degree and duration of the specific anti- 
histamine response to - the drugs and in the incidence 
of side -effects. If the specific response to one drug was 
poor it was usually poor to the others also. 
In people resistant to any of the anti -histamine 
drugs a " normal " response could be obtained by a 
suitable increase in the dose, the chief limiting factor 
being the incidence of unpleasant side- effects. 
In 20 patients with chronic urticaria treated with 
anthisan, in all of whom the weals were suppressed or 
greatly modified, intradermal histamine reactions were 
recorded before and throughout treatment, and the 
modification of the reaction was found to parallel closely 
the response of the urticaria. 
There was considerable variation from one person to 
another in the dose required to suppress the urticaria, 
and it is suggested that many of the reported failures 
in the treatment of urticaria with anti- histamine drugs 
were in patients resistant to the drugs, and that higher 
doses or more potent drugs might have produced 
satisfactory effects. 
The results are discussed, with special reference to the 
importance of the differences in potency and duration of 
action of the different drugs and to the variation from 
one person to another in the response to any one. A 
possible factor in determining differences in duration 
of action is noted, and the significance of the variation 
in response from one person to another is emphasised. 
Our thanks are due to Dr. J. T. Ingram for access to, and 
help with, the cases ; Dr. B. N. Halpern for a supply of 
3277 R.P. ; Dr. W. R. Thrower for a supply of anthisan ; 
and the Medical Research Council for an expenses grant to 
one of us (W. A. B.) to defray the cost of the work. 
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THE histamine antagonist, N(2- dimethylaminoethyl) 
N( p- methoxybenzyl)2- aminopyridine maleate, was intro- 
duced as ` 2786 R.P.' by Bovet and Walthert (1944). 
Later known on the Continent as ` Neoantergan ' ¿nd 
in this country. as ' Anthisan ' or mepyramine maleate, 
it was soon recognised as the most powerful and specific 
of the histamine antagonists. Halpern and Ducrot (1946) 
were responsible for a new series of anti -histamines, 
derivatives of phenothiazine, the most active of which 
was N(2- dimethylamino- n- propyl) phenothiazine hydro- 
chloride or ` 3277 R.P.' Experiments on animals (Halpern 
et al. 1946) showed that this was a much more powerful 
histamine antagonist than anthisan, and after clinical 
trial it was marketed in France as ` Phenergan ' and is 
now obtainable in this country under the same name. 
Though some clinical reports on the use of phenergan 
in France have appeared (Vallery -Radot et al. 1947, 
1948, Halpern and Hamburger 1948) and seem to indicate 
that it is the most effective histamine antagonist available, 
no detailed comparison of phenergan and anthisan has 
been made. 
We give here the results of a comparison of these two 
drugs from both pharmacological and therapeutic studies 
in man. 
PHARMACOLOGICAL OBSERVATIONS 
While quantitative methods have been widely used 
in animals and in isolated animal tissues for comparing 
different histamine antagonists, comparative studies in 
man have been for the most part qualitative, though 
the desirability of applying quantitative methods in 
this field has been emphasised by Bain et al. (1948b). 
In communications to the British Pharmacological 
Society, Bain et al. (1948a) described methods they had 
developed for this purpose and some of the results 
obtained. That work will be published in detail elsewhere, 
but the salient points which are relevant to the subject 
of the present paper are summarised here. 
Firstly, it was shown that, in any given person, if 
graded doses of histamine are injected into the skin, and 
the areas of the resulting weals or flares measured, the 
relationship between the logarithm of the dose and the 
effect is linear over at least a three -hundredfold range 
of dosage. 
The volume of fluid injected was 0.06 or 0.1 ml., and the 
dose of histamine base contained in this volume varied 
from 0.01 to 100.0 ¡Lg.-i.e., a ten- thousandfold range. The 
linear relationship usually holds, for both flares and weals, 
over the range 0.01 -3.0 µg.- though in some persons to 
as far as 10.0 n. or more -and its limit is marked by a sharp 
discontinuity, from which point the slopes of the lines rise 
very steeply. This discontinuity will be discussed elsewhere. 
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We have pleasure in suggesting as Christmas presents, the following cases which offer a fair 
selection of wines and spirits. We shall be happy to despatch any of these to you or your friends on 
receipt, of your order. 
Case No. Price per case 
1. 1 Bottle South African Sherry, Pale Medium Dry £ s. c1. 
1 Bottle Parliament Port. Fine old Ruby 1 16 0 
2. 1 Bottle San Sebastian Sherry, Fine Amontillado 
1 Bottle Big Ben Port, Vintage wine matured in wood 2 2 0 
3. 1 Bottle Raleigh Sherry, Pale Golden 
1 Bottle Cocktail Gin, 50° Proof ... 2 6 6 
4. 1 Bottle St. Vincent Sherry, ` Very Fine Amontillado 
1 Bottle Madeira, Bual 1878 ... 2 10 0 
5. 1 Bottle Cognac, Very Superior Old Pale 
1 Bottle Parliament Port. .Fine Old Ruby 3 0 0 
6. 1 Bottle San Sebastian Sherry, Fine Amontillado 
1 Bottle Cocktail Sherry, Pale Fino Solera 
1 Bottle Speaker Sherry; Oloroso Particular, Golden 3 6 0 
7. 5 Bottles Claret, Chateau Bellevue 1947 
-Bottle Armagnac, Vintage 1936 ... ... ... ... 3 8 0 
8. 5 Bottles Burgundy, Cotes de Beaune Villages 1947 
l- Rntt.le f!ognac, V_ezy S'nperiar 0161 Pale 3 12 O 
9. 2 Bottles White Burgundy, Pouilly Fuissé 1949 
2 Bottles Moselle, Piesporter Michelsberg 1950 
2 Bottles Hock, Rüdesheimer Hauserweg Riesling 1949... 4 3 0 
- 
T 
10. 1 Bottle Charterhouse Scotch Whisky 
1 Bottle Big Ben Port, Vintage wine matured in wood 
2 Bottles Claret, Cru Pins de Fleurs 1934 ... ... ... 4 7 0 
1.1. 2 Bottles Claret, Chateau Canon 1943 
1 Bottle San Sebastian Sherry, Fine Amontillado 
2 Bottles Champagne, Duc de Belfort .. 5 0 0 
12. 1 Bottle Cognac, Grande Champagne 1929 
2 Bottles Champagne, Veuve Clicquot 1942 6 0 0 
13. 1 Bottle Charterhouse Scotch Whisky 
2 Bottles Champagne, Pommery and Greno 1945 
. 2 Bottles Vintage Port, Quinta do Noval'1934 ... 
PRICES INCLUDE CARRIAGE AND PACKING. 
PLEASE SEE OTHER SIDE 









Below we offer a small selection of wines and spirits. In addition we hold extensive stocks of 
Vintage Port, Claret and Burgundy for laying down and present drinking, and also Champagne of all 
good Shippers, with adequate landing age. We have a wide selection of Hock; and Moselle. 
D 
PORT. 
Big Ben, Vintage wine matured in 
Lodge ... ... ... ... 


























' Macon Blanc, 1950 ... 
Pouilly Fuissé, 1949 ... 
Meursault, Les Casse Têtes, 
1947 ... 
HOCK. 
\ieI tcincr I)onital. 1949 
LicbfrtiumiIch Superior, 
1949 ... ... ... 
Kallstadter Steinacker 
Riesling, 1949 ... ... 
Oestricher Gottestal 
Riesling, 1949 ... .... 
Rauenthaler Berg Spätlese, 
1949 ... . .. 
. 
MOSELLE. 
Kaseler Lorenzberg, 1950... 
Piesporter, 1949 ... ... 
Erdener Treppchen, 1950 
Reiler Goldlay Spätlese, 
1949 . 
CHAMPAGNE. 
Duc de Belfort, Extra Dry, 
Extra Quality ... ... 
SCOTCH WHISKY. 
Charterhouse, Fine Old ... 
IRISH WHISKEY. 
Ballagary, Old Liqueur ... 
COGNAC. 
Good Quality ... ... 
Very Superior Old Pale ... 
Exhibition, Fine Old 
Liqueur ... ... ... 





































South African Sherry, Pale Medium 
and Pale Selected Dry ... ... 
Cocktail, Pale Fino Solera, Very Dry 
San Sebastian, Fine Amontillado ... 
The Speaker, Oloroso Particular 
Golden ... ... 
MADEIRA. 
Tears of Angels, Very Old, Pale and 
Dry ... ... 
Very Choice Bual, 1878 
CLARET. Bottle. 
St. Julien ... ... ... 7 /- 
Château Bellevue, Macau, 
1947 ... ... ... 8 /6 
Chateau Nenin, Pomerol, 
1945 ... ... ... 11 /6 
Chateau Canon,St. Emilion, 
1943 ... ... ... 16 /6 
Château Latour, Pauillac, 
1944 ... ... ... 20 / 
Château Langoa Barton, 
St. Julien, 1934... ... 20 /6 
WHITE BORDEAUX. 
Graves, Light Dry ... 6 /9 
Château Dumême, Medium 
8 /6 
-eliA team Couhins Graves; 
1949 .. 9 /6 
Château Grillon, Barsac, 
1949 :.. 13 /6 
BURGUNDY. 
Beaujolais ... ... ... 8 /6 
Côtes de Beaune Villages, 
1947 ... ... ... 10 /- 
Beaune 1947 10 /6 
Nuits St: Georges, 1945 ... 16 /- 
4' ALL CONSIGNMENTS OF 6 BOTTLES OR MORE ARE SENT CARRIAGE PAID. 
46 BY RAIL OR CJ+RRIER. 
ts 
BLOCK, GREY & BLOCK, Ltd., 26, South Audley Street, London, W.1 
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Secondly, it was shown that, after the administration 
of an adequate dose of a histamine antagonist by mouth, 
the log -dose response curve to intradermal histamine 
shifts so that it occupies at any given time a new position 
such that, in the conditions of the experiments and 
so far at least as the weal responses are concerned, 
there is an approximately equal percentage reduction 
of weal area over the range of test doses from 0.1 to 
10.0 µg. 
It is clear that these two facts made it possible to 
undertake in man a more precise comparison of histamine 
antagonists than had hitherto been possible, and we have 
applied them in the first instance to a study of the relative 
weight- for -weight potencies and the relative durations 
of action of different drugs. 
After the administration of a histamine antagonist by 
mouth the anti -histamine effect rises to a maximum and 
then tails off, the time relations depending on the condi- 
tions of the experiment, the drug used, and the individual. 
The extent of reduction of the intradermal weal response 
at the point of maximum action of any histamine 
antagonist depends, of course, on the conditions of the 
experiment, the dose used, and the individual. 
By measuring in any person the maximum shift of the 
dose- response curve to intradermal histamine for each of 
several oral doses of a histamine antagonist, expressing the 
maximum shift for each oral dose as the mean percentage 
reduction in weal area, and plotting this as ordinate 
against the logarithm of the dose of antagonist as 
abscissa, the relationship between dose and effect for 
that antagonist in that person 
By making such observations in a group of people, 
and taking the mean maximum percentage reductions of 
weal areas in the group for each oral dose of the 
antagonist, a mean dose -response curve for that drug is 
determined. By repeating such observations with other 
histamine antagonists in the same group of people mean 
dose- response curves for these other drugs are obtained, 
and from such data the mean relative weight -for -weight 
potencies of the various substances can be estimated. 
The results of such a comparison of anthisan and 
phenergan are shown in fig. 1. 
In these experiments the same six people were given, on 
different occasions, oral doses of 50, 100, and 300 mg. of 
anthisan and of 25, 50, and 100 mg. of phenergan, and the 
maximum reduction of weal area was determined for each dose 
of each drug by at least three intradermal test doses of 
histamine (10.0, 1.0, and 0.1 µg.) given before, and at intervals 
after, ingestion of the anti- histamine. 
The areas of the weals were obtained by inking the weal 
outline on the skin 5-10 minutes after each injection, trans - 
ferring to millimeter graph paper, and computing directly. 
The results were calculated from these measurements and not, 
as might have been done, from the regression lines most 
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ORAL DOSE OF HISTAMINE ANTAGONISTS (mg.) 
Fig. I- Relationship between dose and maximum anti -histamine response 
for phenergan and anthisan. Mean results from six people. Mean 
doses to give 50 % reduction of weal area are shown on lower abscissa, 
and theoretical mean doses to produce 100 % reduction on upper 
abscissa. 
As will be seen from fig. 1, phenergan is the more power- 
ful drug. Thus, in our six people, whereas a 50% reduction 
of weal area was produced by about 40 mg. of phenergan, 
about 275 mg. of anthisan was required to produce the 
same mean effect. The mean doses theoretically 
required to abolish completely the intradermal histamine 
reaction were -assuming the dose -response graphs to 
be linear throughout their course-450 mg. of phenergan 
or 3200 mg. of anthisan. 
We have compared other histamine antagonists by this 
method, but the results will be published elsewhere. It 
is sufficient to point out here, first, that phenergan is 
by far the most powerful of the drugs we have encountered 
and is thus a convenient standard against which the 
potency of others can be compared ; and second, that 
such comparisons of potency are facilitated by the 
fact that the regression lines for the different drugs are 
parallel, so there is a simple ratio relating the mean dose 
of any two antagonists to give equal mean responses. 
From the results shown in fig. 1 it is evident that about 
seven times the amount of anthisan is required to produce 
the effect of a given dose of phenergan ; we can express 
this difference in potency by saying that, in relation to 
the mean maximum effect produced by a single dose, 
phenergan is on the average seven times more active, 
weight for weight, than anthisan. 
Though the differences in potency among histamine 
antagonists are of considerable interest they are probably 
of much less practical importance than differences in the 
duration of action of the various drugs ; for, whereas 
differences in potency can be allowed for by adjustment 
of the dose, it is on the duration of action that the 
frequency of administration will depend, and this is 
clearly an important factor in a class of drugs whose use 
is associated with a high incidence of unpleasant side - 
effects, which, when they occur, are usually most obvious 
for a period following the absorption of each successive 
dose. 
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We have therefore attempted to apply quantitative 
methods to the study of these differences, the problem 
being to obtain some measure of the relative durations 
of action such that the differences could be expressed in 
a fashion analogous to that which we used to express 
differences in potency. The difficulties in measuring the 
degree of anti -histamine effect when this has almost 
disappeared are obvious ; so we have made our com- 
parisons by estimating the times taken for the maximum 
anti -histamine action of single approximately equi- effective 
doses of the different drugs to be reduced by 50 %. 
Even the estimation of such " half- action " times 
presents difficulties, especially with the long -acting drugs, 
but the results of different experiments are remarkably 
consistent. 
The results of these observations are represented 
diagrammatically in fig. 2. The experiments were made 
on groups of from four to eleven people, and the figures 
given for each drug are the average of three separate 
experiments in each of which the mean results have been 
used. The intradermal test -dose of histamine was either 
FO or 3.0 N.g. ; and, before ingestion of the drug, the 
normal response to this dose Was determined from at 
least three test injections. The drug was then taken with 
a cup of coffee two or more hours after a light breakfast. 
The onset and disappearance of the anti -histamine effect 
was determined by duplicate injections of the test -dose 
of histamine at suitable intervals -short ht first, and 
I I 1 1 1 1 1 1 1 i I I 1 1 1 1 1 1 I I 1 1 1 1 1 
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MINUTES 
Fig. 2 -Time relationships between onset and disappearance of anti- 
histamine effect with approximately equi- effective doses of phenergan 
and anthisan. Mean results of three experiments, each on four or 
more people, with each drug. Times to maximum and to half 
maximum action for each drug are marked. 
longer in the later stages of the experiment. By this 
means it was possible to estimate graphically for each 
person the degree of maximum effect, the time for the 
establishment of this, and the time for the reduction of 
the maximum effect by half. 
The great individual variation in the duration of 
action, as already pointed out by Bain et al. (1948b), 
is well shown in these experiments but will be dealt with 
in detail elsewhere. It is sufficient here to point out 
that, though the mean times from ingestion of the drugs 
to the point when half -action is reached are about 1360 
minutes for phenergan and 430 minutes for anthisan, 
the range is 700 -1800 minutes for phenergan and about 
250 -1000 minutes for anthisan. 
16 
But, in comparing the times taken for the different ' 
drugs to reach half- action, it seems desirable to take 
into account the well- marked difference in the rate of 
establishment of maximum action for each drug, and to 
state the time from maximum action to half- action rather 
than from ingestion to half -action. The average times 
for maximum action to be established in the conditions 
of our experiments were 190 minutes for phenergan and 
120 minutes for anthisan. The mean times from full to 
half- action were thus 1170 minutes (19 hours 30 minutes) 
for phenergan, and 310 minutes (5 hours 10 minutes) for 
anthisan. 
Hence the maximum effect of a single dose of phenergan 
takes over 33/4 times as long to be reduced by half as 
does the maximum effect of an approximately equipotent 
dose of anthisan, or the maximum effect of a single dose 
of anthisan is reduced by half in about a quarter of the 
time required for the same degree of reduction after an 
equipotent dose of phenergan. 
It is thus clear that phenergan differs much from . 
anthisan in both its potency and its duration of action. 
It is '7 times as potent, in the sense that to produce the 
same mean maximum effect as would be produced by 
a given dose of anthisan only a seventh of that amount 
of phenergan is required ; and its duration of action is 
33/4 times greater than that of anthisan, in the sense that 
the mean time required for the reduction of the anti- 
histamine response from maximum to half maximum, 
after doses of the two drugs producing approximately 
equal mean maximum effects, is 33/4 times as long. 
It is also evident from these results that both weight - 
for- weight potency and duration of action must be 
important in relation to the relative clinical effectiveness, 
and hence the intelligent therapeutic use, of histamine 
antagonists. It is likely too that a fair idea of the thera- 
peutic possibilities of any new drug of this class could be 
obtained from experiments of the kind we have described. 
But such observations leave out of account the side - 
effects of the drugs, and these constitute, as Bain 
et al. (1948b) have pointed out, an important limiting 
factor in the usefulness of histamine antagonists. It 
might be argued that side -effects could be dealt with as 
" all or none " phenomena, but the number of people in 
our studies has generally been insufficient for this purpose. 
In any event the clinical significance of side -effects is not 
quantal but depends on their severity, the reactivity 
of the patient, and other such factors. The reactivity of 
the patient may vary with circumstances, depending, 
for example, on whether he is up and about or in bed, is 
mentally relaxed or doing work involving mental concen- 
tration ; it may also vary from day to day for no 
apparent reason- though seeming differences in this 
category may sometimes depend on how the questions 
are framed by the observer. 
Though the assessment of the incidence and severity 
of side -effects is complicated, two facts are of out- 
standing practical importance : (1) some tolerance is 
often acquired to these when administration is continued 
for a few days ; and (2) with the long -acting drugs, such 
as phenergan, the specific anti -histamine effect of a 
single dose long outlasts the side -effects. This last obser- 
vation, together with the long duration of action of the 
specific anti -histamine effects of phenergan, suggested 
the possibility of using phenergan clinically in a single 
daily dose given at night. In this way drowsiness would 
but contribute to sleep, and any other side -effects would 
pass unnoticed ; yet the specific histamine antagonism 
would continue through the following day. 
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THERAPEUTIC OBSERVATIONS 
Twenty patients with chronic urticaria, who had been 
treated for various times with anthisan, were accordingly 
put on one dose of phenergan each night, and the dose 
was adjusted in an attempt to get clinical effects approxi- 
mating as closely as possible to those obtained with 
anthisan. We have thus been able to make a controlled 
clinical comparison of these two drugs ; to establish the 
approximate equivalent therapeutic doses ; to assess 
the relative merits of equitherapeutic doses in relation 
to side- effects ; and to show that the hypothesis which 
led to trial of the nightly dose routine was justified. 
In these observations the degree of histamine antagon- 
ism was assessed partly by the response of the urticaria, 
partly by the dermographic reaction (when this was 
present), and partly by the reduction of weal areas in 
intradermal histamine tests. A close parallel has already 
been shown in the degree of response of all three 
phenomena to histamine antagonists (Bain et al. 1948b). 
Since all the subjects were outpatients, it was impossible 
to make observations as often as was desirable, and it was 
usually 5 -7 days after the control tests and the institution 
of therapy that the patients were seen again. Though most 
patients noted a pronounced improvement in their condition 
after 24 hours on anthisan, some noted little improvement 
with phenergan in the first 2 or 3 days. Thus, with phenergan 
given nightly the cumulative effect over some days was 
sometimes clearly necessary to establish an adequate thera- 
peutic level. But once this level was reached there was little 
evidence of further cumulation. The initial lag in the onset 
of the therapeutic effect with nightly doses could presumably 
be obviated by giving a single high " loading " dose at the 
outset, or by giving ordinary doses three times a day until 
the desired action was obtained and following this with nightly 
" maintenance " doses. In the observations described below, 
however, we are concerned only with nightly doses of 
phenergan. 
A summary of the results with the two drugs is given 
in table I, and a diagrammatic representation of the type 
of quantitative data obtained from some of the patients 
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Fig. 3 -Type of quantitative data obtainable in clinical comparison of histamine antagonists. The 
patient, a man aged 23, had urticaria for 2 years, associated wi h dermographism. Explanation 
of +s as in table I. Mean diameters of flare (thin line) and weal (thick line) in cm. Intradermal 
histamine reaction from 0.05 ml. of 0'01% w/v histamine acid phosphate. Dermographic 
reaction from different traumatising stimuli (mean of four measurements). In this patient 
50 mg. of phenergan a day had effect of between 600 and 900 mg. of anthisan a day. 
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caria Side -effects 
1 M 23 2 yr. + + + 100 t.i.d. 2 + + + Nil 50 4 0 Nil 
Phenergan 
200 t.i.d. 14 + + + 
300 t.i.d. 4 0 + + + 
2 F 40 8 mos. + + + 100 t.i.d. 1 + + Nil 50 2 + + Nil Phenergan 
200 t.i.d. 1 + + Nil 75 4 + Nil 
300 t.i.d. 10 + + 100 5 0 Nil 
300 q.i.d. 2 0 + + 













+(, /, -1 hr. A.M.) 
+(1/,-1 hr. A.M.) 
Anthisan 
100 2 + + +(2 -3 hr. A.M.) 
4 F 30 7 mos. + + + 200 q.i.d. 6 + + + 50 5 0 Nil 
Phenergan 
5 F 38 13 mos. + + 100 t.i.d. 24 + Nil 25 1 + +(1 -2 hr. 
A.M.) Phenergan 
200 t.i.d. 1 + + 50 6 0 +(1 -2 hr. A.M.) 
300 t.i.d. 1 0 + + 
6 F 29 10 mos. + + + 100 t.i.d. 7 + + 75 1 + + +(1 -2 hr. A.M.) 
None 
200 t.i.d. 12 + + + 100 5 0 +(1 -2 hr. A.M.) 
200 q.i.d. 5 0 + + 
7 M 30 7 mos. + + + 100 t.i.d. 5 + Nil 25 5 0 Nil None 
100 q.i.d. 12 0 Nil 
8 F 45 11 mos. + + 100 t.i.d. 1 + + + + 75 2 + Nil Phenergan 100 3 0 Nil 
9 F 39 3 yr. + + + 100 q.i.d. 8 0 Nil 25 1 0 Nil None 50 6 0 Nil 
10 F 28 5 mos. + + + 100 q.i.d. 4 + + + 50 1 + Nil Phenergan 100 5 + +(' /, -1 hr. A.M.) 
200 3 0 +(' /, -1 hr. A.M.) 
11 M 67 5 mos. + + + 100 t.i.d. 3 + + + + 25 13 + +(2 -3 hr. A.M.) Phenergan 
12 F 39 8 mos. + + 100 t.i.d. 4 + Nil 25 2 + Nil None 
100 q.i.d. 16 + + 
13 F 47 2 yr. + + 100 q.i.d. 11 0 + 25 6 0 Nil Phenergan 
1 14 F 50 12 mos. + + 100 q.i.d. 3 + + Nil 50 2 + +('/, -1 hr. A.M.) Phenergan 
1 
200 t.i.d. 3 + + 100 3 + +(' /, -1 hr. A.M.) 
200 q.i.d. 8 + + 125 2 0 Nil 
15 M 70 6 mos. + + + 100 b.i.d. 5 + + 25 3 0 +(5 -15 min.A.M.) Phenergan 
16 M 44 6 yr. +t 100 t.i.d. 24 0 Nil 25 3 0 Nil None 
200 t.i.d. 2 0 + 
17 F 47 3 mos. + + 100 t.i.d. 4 0 +# 25 2 0 Nil Phenergan 
18 F 19 8 mos. + + + 100 t.i.d. 6 + + Nil 50 4 0 Nil Phenergan 
19 F 68 5 mos. + + 200 t.i.d. 8 + + 100 3 0 Nil Phenergan 
20 F 54 4 mos. + + 100 b.i.d. 2 + + 25 2 0 Nil Phenergan 
Occasional diarrhoea and vomiting. 
t Associated with attacks of giant urticaria every 2 -3 days. 
# Severe nausea and vomiting. 
Severity of urticaria : + An occasional weal. Severity of side -effects : + Slight symptoms on questioning. 
+ + A few weals. + + Complaint of mild symptoms. 
+ + + A moderate number of weals. + + + Complaint of moderate symptoms. 
+ + + + Profuse weals. + + + + Severe incapacitating symptoms. 
Table I shows that, whereas anthisan had to be 
given three or four times a day in all but 2 cases, a single 
nightly dose of phenergan controlled the urticaria in all 
the patients throughout 24 hours. Only 3 patients on 
anthisan were completely free from side -effects, against 
14 on the nightly dose of phenergan. Many of the 
patients on phenergan felt a little dull and sleepy on 
waking during the first days of therapy -the symptoms 
taking from a few minutes to 4 hours to pass off- 
but in only 5 did this morning drowsiness persist 
throughout treatment. In any event this was the only 
side -effect noted with phenergan and is in contrast to 
the well -marked and persistent sleepiness and light- 
headedness which occur with anthisan and may be 
complicated, as it was in 4 of our patients, by occasional 
or persistent gastro -intestinal disturbances. 
Of the 20 patients, only 1 preferred anthisan, 14 
preferred phenergan, and 5 had no preference. The 
14 patients who preferred phenergan were quite definite 
about their preference ; most had experienced side -effects 
with anthisan, and found none, or only the transitory 
morning sleepiness, with phenergan ; only 1 had been 
free from side- effects with both drugs. Of the 5 who had 
no preference, 1 had experienced mild side -effects with 
anthisan and had morning sleepiness with phenergan ; 
of the other 4 all were free from side -effects with phener- 
gan, 3 of them had no side -effects with anthisan, and 1 
had given evidence of slight symptoms with anthisan 
on questioning. 
It is clear, then; that with phenergan in nightly doses 
the appreciated incidence of side -effects and the duration 
and severity of these when they develop are much less 
than with equitherapeutic doses of anthisan given, as it 
must be, two, three, or even four times a day ; and it 
follows that in patients intolerant of the necessary doses 
of anthisan adequate therapeutic effects can usually be 
obtained by easily tolerated nightly doses of phenergan. 
Whether equal freedom from side -effects could be 
attained by giving the daily amount of phenergan in 
divided doses remains to be seen, but the method -we 
have adopted seems to have everything to recommend it, 
including the minor consideration that the patient may 
perhaps derive benefit rather than the reverse from the 
hypnotic effect of the drug taken at night. 
By comparing the doses of anthisan and of phenergan 
required to produce approximately equal therapeutic 
results we can derive a measure of the relative thera- 
peutic potencies of the two drugs. Table i shows that in 
some cases (4, 8, 10, 14, 15, 18, 19, and 20.) the dose of 
phenergan used produced a greater therapeutic effect 
than did the dose of anthisan in the earlier period of 
treatment ; these, and cases 3 and 11, in which the 
urticaria was not abolished, have been ignored in this 
comparison. 
In each of the remaining 10 cases the daily doses of 
anthisan and of phenergan which gave approximately 
TABLE II- EQUIDALFINT THERAPEUTIC DOSES IN 10 PATIENTS 
Case no. 
Equivalent daily doses (mg.) 
R atio anthisan/ 
phenergan 
Anthisan Phenergan 
1 750 50 15 
2 1200 100 12 
5 900 50 18 
6 800 100 8 
7 400 25 16 
9 400 25 16 
12 400 25 16 
13 400 25 16 
16 300 25 12 
17 300 25 12 
.. Av. 14.0 
equal therapeutic effects, and the 
ratios which these doses bear to 
one another, are shown in table ii. 
It will be seen from the last 
column of table Ii that in these 
ten patients the therapeutic effect 
of a given dose of phenergan was 
produced by from 8 to 18 times, 
or by an average of 14 times, that 
dose of anthisan. Thus, on the 
average, 25 mg. of phenergan a 
day is the approximate therapeutic 
equivalent of 350 mg. of anthisan 
a day, or of three divided doses 
each of about 115 mg. Similarly, 
a daily dose of 50 mg. of phenergan 
is the therapeutic equivalent of 
about 700 mg. of anthisan a day, 
or of three divided doses of about 
230 mg. 
Thus, while phenergan is only 
about 7 times as potent as anthisan 
when compared in terms of the 
single doses required to produce 
the same intensity of effect it is 
almost 14 times as potent as 
anthisan when compared in terms 
of the relative doses per day 
required to maintain a similar 
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level of anti -histamine activity. The difference in the 
duration of action of the two drugs is clearly the main 
factor determining the difference between these two 
measures of potency. 
The differences between anthisan and phenergan 
which we have already described are essentially quanti- 
tative, but it seems that there may also be a qualitative 
difference, which might conceivably be of clinical signifi- 
cance in some circumstances and, in any event, is worthy 
of mention. 
In our first set of experiments on the duration of action 
of the different anti -histamines we were surprised to find 
that, though the histamine reaction was diminished by 
anthisan from the first, it was temporarily increased or 
potentiated by phenergan. Thus half an hour after 
ingestion of anthisan the mean reduction in the histamine 
response was 10 %, whereas half an hour after ingestion 
of phenergan there was a mean increase of 10% in the 
response, the weal areas in all six persons showing some 
increase above normal. Half an hour later still the weal 
response was normal once more, after which it diminished 
rapidly to give the usual maximum anti- histamine effect 
3 hours from the time the phenergan was taken. In 
subsequent experiments this phenomenon has been 
observed in only some of our subjects and has not shown 
on the mean curve ; we have consequently indicated in 
fig. 2 alternative routes for the onset of the anti- histamine 
effect of phenergan. A similar potentiating action of 
phenergan on the histamine response has often been seen 
in experiments where the drugs are administered locally 
to the skin in the manner briefly described in a previous 
paper (Bain et al. 1948b). The effect most commonly 
occurs when the phenergan and histamine are injected 
simultaneously: 
Kapeller -Adler (1949) has shown that phenergan, but 
not anthisan, will inhibit histaminase in vitro ; so the 
potentiating action of phenergan which we have described 
I may possibly be due to an inhibiting effect on histaminase. 
But to what total extent histaminase may be inactivated 
by therapeutic doses of phenergan, or how long the effect 
may persist, it is impossible to say from experiments of 
the type we describe, because the effect itself, manifested 
by the potentiation of the histamine weal response, 
becomes quickly masked by the establishment of the 
specific anti -histamine action of the drug. However, if 
phenergan is really potent as an inhibitor of histaminase, 
then small doses of the drug in persons relatively 
resistant to the anti -histamine effects might produce an 
exacerbation of any symptoms due to histamine release ; 
such untoward effects could presumably be countered by 
increasing the dose. 
SUMMARY 
The histamine antagonists ` Anthisan ' (mepyramine 
maleate, ` Neoantergan,' ` 2786 R.P.') and ` Phenergan ' 
(` 3277 R.P.') are compared quantitatively as regards 
their weight- for -weight potencies, durations of action, 
and therapeutic efficacies in chronic urticaria. 
The relative potencies of the drugs are compared by 
estimating the oral doses of each required to produce the 
same degree of reduction of the intradermal histamine 
weal response. Phenergan is shown to be about seven 
times as potent as anthisan. Thus 25 mg. of phenergan 
will produce, on the average, about the same maximum 
effect as 175 mg. of anthisan. 
The relative durations of action are estimated from the 
times taken for the maximum effect of approximately 
equipotent doses of the drugs to be reduced by half. 
The mean half- action time for phenergan is 191/8 hours, 
and for anthisan 51/8 hours. Thus the maximum effect of 
a given dose of phenergan is likely to take 33/, times as 
long to be reduced by half as is the effect of an equipotent 
amount of anthisan. 
Anthisan and phenergan are compared therapeutically 
in twenty cases of chronic urticaria, anthisan having 
been given at the usual intervals but phenergan, because 
of its long duration of action, in a single dose at night. 
Patients who prefer a nightly dose of phenergan to 
equi- effective doses of anthisan are usually those who 
experience less side -effects with phenergan than with 
anthisan, whereas those who express no preference have 
usually experienced no, or only very slight, side -effects 
with anthisan. Of these 20 patients, 14 preferred 
phenergan, and 5 had no preference. 
The relative therapeutic potencies of anthisan and 
phenergan are estimated from the individual ratios 
between the daily dose of anthisan and the daily dose of 
phenergan required to produce the same therapeutic 
effect. Phenergan is, on the average, 14 times as potent 
as anthisan. Thus, a patient with chronic urticaria whose 
condition is controlled by 350 mg. anthisan a day, or 
120 mg. three times a day, is likely to show a similar 
clinical response to 25 mg. of phenergan a day, given in 
a single dose at night. He is also likely to prefer this 
treatment. 
The possibility that phenergan may exhibit an inhibit- 
ing effect on histaminase is noted, and a possible 
consequence of this action is pointed out. 
Our thanks are due to Dr. J. T. Ingram and Dr. F. F. Heller 
for access to, and help with, the patients ; to Dr. G. Achari 
and Miss M. Robinson for help with the laboratory experi- 
ments, and to our willing subjects in these ; to Dr. B. N. 
Halpern and Dr. W. R. Thrower for supplies of the drugs ; 
and to the Medical Research Council for an expenses grant 
to W. A. B. which met the cost of the work. 
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The Quantitative Comparison of Histamine 
Antagonists in Man 
Professor W. A. Bain ( University of Leeds) : The Quantitative Comparison of Histamine 
Antagonists in Man. 
Tills work, done by a small teams at Leeds, is part of a general attempt to apply to pharma- 
cological studies in man methods of a quantitative kind such as have hitherto been applied 
chiefly to animals and to isolated animal tissues. As a starting -point in this quantitative 
approach to human pharmacology histamine and the histamine antagonists seemed ideal 
drugs to use, since histamine produces easily measurable reactions in the most extensive 
and readily available organ of the body and these reactions, as is well known from much 
qualitative work, are readily modified by histamine antagonists. A further consideration 
influencing our choice was the practical desirability of developing methods for assessing 
the relative merits of antihistaminics: this has now become an urgent practical necessity 
in view of the bewildering rate at which new drugs of this class are being introduced and the 
inevitable confusion which this is causing. 
Our first task was to determine the dose -effect relationship for histamine when the drug 
was injected into the skin; and the second to determine in what manner and to what 
extent this was modified by the oral administration of histamine antagonists. From such 
observations we were able to devise means for obtaining quantitative comparative informa- 
tion about three of the four most important practical aspects of the actions of these drugs - 
their relative weight- for -weight potencies, their relative durations of action, and their relative 
therapeutic efficacies. Only the hyoscine -like side actions were not amenable -or were not 
subjected -to quantitative study. 
Our account is necessarily but a brief summary of what we have done. Results are given 
mostly as mean values: statistical treatment of the data is omitted and will be presented 
elsewhere. For information about the various drugs mentioned, and about previous work 
upon them, the reader is referred to the recent reviews by Halpern (1948) and by Hunter 
and Dunlop (1948). 
The dose- response curve to intradermal histamine. 42nd its modification by histamine anta- 
gonists. -The two experimental facts which form the basis of the subsequent observations 
are these: First, if graded doses of histamine are given intradermally to any individual, 
and the areas of the resulting wheals or flares are measured when at their maximum, then 
the relationship between the logarithm of the dose and the effect is linear over at least a 
three -hundredfold dose range -usually from 0.01 µg. to at least. 3.0 µg., and in many 
subjects to as far as 10 µg. or more -after which the slope of the graph increases suddenly. 
Second, after the oral administration of an adequate dose of a histamine antagonist the 
log -dose response curve to intradermal histamine shifts so that it occupies at any given 
time a new position such that, in the conditions of our experiments and as far at least as the 
wheal response is concerned, there is an approximately equal percentage reduction of wheal 
area for each of the test doses of histamine over the range from about 0.03 to at least 10.0 pg. 
'The Author, with Dr. G. Achari, Dr. J. L. Broadbent, Miss M. Robinson, and Dr. Rs P. Warin. 
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These facts are illustrated in fig. 1 which shows the mean results from a set of experiments on five 
subjects. The upper points show the mean wheal areas resulting from the intradermal doses of hista- 
mine indicated on the abscissa, and the graph is drawn through these points by eye. The lower points 
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FIG. 1. -To show normal dose -response curve to intradermal histamine and its modification after 
the oral administration of a histamine antagonist. Mean results from five subjects. Abscissa -dose 
of histamine base in µg., logarithmic scale. Ordinate -wheal areas in sq. mm The upper (open) 
points are normal: the lower (solid) ones were obtained three hours after the ingestion of 25 mg. 
Phenergan (3277 R.P.). For further explanation see text. 
The average percentage reduction in wheal area for all the test doses of histamine was 35.0. The 
lower solid line is drawn to give throughout its course this same percentage reduction of the values 
represented by the normal dose -response graph. It fits the experimental points more closely than 
does the broken line which is parallel to the normal graph. 
The comparison of weight-for-weight potencies. -When a histamine antagonist is taken 
by mouth the antihistamine effect, as gauged by the percentage reduction in the effect of an 
intradermal test dose of histamine, rises to a maximum and then tails off, the time relations 
depending on the conditions of the experiment, the drug used, and the individual. This is 
illustrated in fig. 2 which shows the mean results with various drugs in the same four subjects. 
It is clear that, other things being equal, the extent of the maximum reduction of the hista- 
mine response will depend on the dose of the antagonist, so that in comparing the relative 
potencies of different drugs it is essential to make the comparisons when the action of each 
drug is at its maximum, i.e. when the dose- response curve to intradermal histamine is 
maximally shifted. 
If then, in any subject, the maximum shift of the dose -response curve to intradermal 
histamine is determined for each of several doses of an antagonist, and this maximum 
shift for each dose of the antagonist is expressed as the mean percentage reduction in wheal 
area and plotted as ordinate against log -dose antagonist as abscissa, then the relationship 
between dose and effect for that antagonist in that subject is determined. By making such 
observations in a group of subjects a mean dose -response curve for that antagonist is deter- 
mined. By repeating such observations with other antihistaminics in the same group of 
subjects mean dose -response curves for these other drugs are obtained, and from such data, 
since the dose -response curves for the various drugs are parallel, the mean relative weight - 
for- weight potencies can be readily estimated. 
Fig. 3 shows the results of such a comparison of Phenergan (3277 R.P.), Anthisan (Neoan- 
tergan, 2786 R.P.) and Antistin. 
In these experiments the same six subjects were given, on different occasions, oral doses of 50, 100 
and 300 mg. Anthisan, 25, 50 and 100 mg. Phenergan and 100, 200 and 300 mg. Antistin respectively, 
and the maximum reduction of wheal area was determined for each dose of each drug by at least 
three intradermal test doses of histamine (10.0, 1.0 and 0.1 µg.) given before and at intervals after 
ingestion of the antihistamine. 
The areas of the wheals were obtained by inking the wheal outline on the skin five to ten minutes 
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after each injection, transferring to millimetre graph paper, and computing directly. The results 
were calculated from these measurements. 
Phenergan is clearly the most powerful of these drugs and Antistin the least so. Thus, 
while a 50 % reduction of wheal area was produced by about 40 mg. Phenergan, it required 
275 mg. Anthisan or 600 mg. Antistin to produce the same mean effect. Furthermore, if 
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FIG. 2. -To show the variation in the rate of rise and fall of the antihistamine effect of single doses 
of various histamine antagonists. Mean results from four subjects. Abscissa -time in hours. Ordinate 
-mean percentage reduction below pre -drug level in wheal areas from intradermal test doses of 
histamine. The drugs and their doses are indicated on the figure. The individual points from which 
the graphs are constructed are omitted to avoid confusion. 
we assume that the dose -response relationship remains linear throughout its course, then 
the mean doses of antihistamine theoretically required to abolish the intradermal histamine 
response are 450 mg. Phenergan, 3,200 mg. Anthisan and 7,000 mg. Antistin respectively- 
all of them quite intolerable doses. 
Such comparisons of relative potency are, of course, facilitated by the fact that the regres- 
sion lines for the different drugs are parallel, so that there is a simple ratio relating the mean 
dose of any two antagonists to give equal mean responses. Thus from the results shown in 
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ORAL DOSE OF HISTAMINE ANTAGONISTS IN MG. 
Fio. 3. -To show relationship between dose and maximum antihistamine response for Phenergan, 
Anthisan and Antistin. Mean results from six subjects. Abscissa -oral dose of drug in mg. on 
logarithmic scale. Ordinate -mean percentage reduction in wheal areas. Graphs A, B, and C are 
for Phenergan, Anthisan and Antistin respectively. Mean doses to give 50 % reduction in wheal area 
are indicated on lower abscissa, and theoretical doses to produce 100 % reduction on upper abscissa. 
For further explanation see text. 
10,000 
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of Antistin, is required to produce the effect of a given dose of Phenergan. We can express 
these differences by saying that, in relation to the maximum effect produced by a single dose, 
Phenergan is seven times more active, weight for weight, than Anthisan, and fifteen times 
more active than Antistin. Phenergan, indeed, is by far the most powerful drug of this 
class which we have encountered and is thus a suitable standard with which the potencies 
of others can be compared. 
Since this method of determining and comparing equi- potent doses of histamine antago- 
nists is of general applicability it is convenient to express the relative potencies of Phenergan 
and any other antihistamine in terms of what we propose to call the "Mean Potency 
Quotient" (M.P.Q.), and to define this as the quotient obtained when, for any particular 
antagonist, the mean dose required to produce a given effect at the time of maximum action 
is divided by the mean dose of Phenergan required to produce the same effect. The 
M.P.Q. of Anthisan is thus approximately seven, signifying that, as far as the maximum 
antihistamine effect of single doses upon the skin capillaries is concerned, seven times as 
much Anthisan is required to produce the same effect as a given dose of Phenergan, or that 
Anthisan is weight for weight one -seventh as potent as Phenergan, or that Phenergan is 
weight for weight seven times more potent than Anthisan. Similarly, the M.P.Q. of Antistin 
is fifteen. It should be noted that this method of expressing relative potencies states how 
much more potent Phenergan is than the drug with which it is compared. This convention 
is adopted in order to avoid fractional quotients. The reciprocal of the M.P.Q. expresses, 
of course, the potency of any drug as a fraction of the potency of Phenergan. 
Comparison of durations of action. -From a practical point of view differences in potency 
among histamine antagonists are probably of less importance than differences in the dura- 
tions of action; for it is on this latter property that the frequency of administration will 
depend, and this is an important matter in a class of drugs the use of which is so often asso- 
ciated with unpleasant or disconcerting side -effects and where such effects are usually most 
evident for a period following the absorption of each successive dose. Fig. 2 gives some 
idea of the marked differences in the duration of action of some of these drugs; but our 
problem was to obtain a measure of the relative durations of action such that the 
differences could be expressed in a fashion analogous to that which we have used for express- 
ing differences in potency. It is evidently impossible to estimate the relative times for the 
disappearance of the action and so our comparisons have been made by estimating the 
times taken for the maximum antihistamine effect of single approximately equi- effective 
doses of the different drugs to be reduced by 50 %. 
The experiments were carried out on groups of from 4 to 11 subjects. The normal response to 
intradermal histamine was determined by at least three injections of 1.0 or of 3.0 µg. histamine. 
The drug was then taken with a cup of coffee two or more hours after a light breakfast. The onset 
and disappearance of the antihistamine effect was determined by duplicate injections of the test 
dose of histamine at suitable intervals. It was thus possible to estimate graphically for each subject 
both the degree of maximum effect and the time for establishment of this, together with the time 
for its reduction by half. The graphs in fig. 2, already referred to, were obtained in this way. They 
are the average results in four subjects and represent a single experiment. Fig. 4 shows the mean results 
from three such experiments for the drugs Phenergan, Anthisan and Antistin respectively. In this 
the times to maximum and to half maximum action are indicated on the graph for each drug. 
There is, of course, great individual variation among the results, but the mean values 
from different experiments are remarkably consistent. Thus while the mean times from 
ingestion to half action are about 1,360 minutes for Phenergan (1,375, 1,320 and 1,375 
minutes) and about 430 minutes for Anthisan (400, 510, 390 minutes) the range among 
individual subjects is from 700 to 1,800 minutes for Phenergan and 250 to 1,000 minutes 
for Anthisan. 
It will be seen from fig. 4 that Anthisan and Antistin reach full action in about two hours 
and Phenergan in just over three, and that the mean times from full to half action in these 
experiments are thus 1,170 minutes (19 hr. 30 min.) for Phenergan, 310 minutes (5 hr. 10 min.) 
for Anthisan and 210 minutes (3 hr. 30 min.) for Antistin. 
As this method of determining and comparing the half- action times after oral adminis- 
tration is applicable to any histamine antagonist, and as Phenergan is by far the longest 
acting of the drugs we have studied, it is convenient to express the relationship between the 
half -action time for Phenergan and that for any other antagonist by what might properly 
be called the "Mean Half -action Quotient ", but which we propose to call the "Mean Dura- 
tion Quotient ", or M.D.Q., which we define as the quotient obtained when the half -action 
time for Phenergan is divided by the half -action time for the drug with which it is compared. 
This relates the half -action time of any particular antagonist and Phenergan by expressing 
the half -action time of Phenergan as a multiple of the half -action time of the drug with 
which it is compared. This convention avoids fractional quotients. 
Thus the M.D.Q. of Anthisan is 3.8, signifying that the maximum effect of a single dose 
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of Phenergan takes about three and three- quarter times as long to be reduced by half as 
does the maximum effect of an approximately equi -potent dose of Anthisan, or that the 
maximum effect of a single dose of Anthisan is reduced by half in about a quarter of the 
time required for the same degree of reduction after an equi- potent dose of Phenergan. 
Similarly, the M.D.Q. of Antistin is 5.6. 
The remarkable similarity between the half -action times for Phenergan and Anthisan when 
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FIG. 4. -To show mean time relationships between onset and disappearance of antihistamine effect 
with approximately equi- effective doses of different antihistamines administered orally. Mean results 
from three experiments, each on four or more subjects, with each drug. Abscissa -time in minutes 
on logarithmic scale. Ordinate -mean percentage reduction in wheal area. Curves A, B, and C 
are for Phenergan, Anthisan and Antistin respectively. Times to maximum and to half maximum 
action are indicated for each drug. For further explanation see text. 
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FIG. 5. -To show mean time relationships between onset and disappearance of antihistamine effect 
when the antihistamine drugs are administered locally to the skin and the test doses of histamine are 
injected to these infiltrated areas. Results from 14 subjects. Dose of antihistamine-0.2 ml. of 0.1 
w /v. Test dose of histamine -1 -5 pg. base in 0.05 ml. Injections at zero time -i.e. of histamine and 
the antagonist simultaneously, were of 0.2 ml. containing 0.1 % w/v of antihistamine and 1.5 µg. 
histamine base. Indicated on graphs are the times from administration to half -action of the various 
drugs. For further explanation see text. 
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to the skin, in the manner briefly described in a previous paper (Bain, Hellier and Warin, 
1948) and extended and reported on in more detail by Achari et al. (1948), is worthy of 
note. The results of these experiments are shown in fig. 5. It will be seen that the mean 
times for maximum action to be reached in these circumstances were about 100 minutes 
for Phenergan and 10 minutes for Anthisan, while the mean times from maximum to half - 
action were 1,250 minutes (20 hr. 50 min.) for Phenergan and 410 minutes (6 hr. 50 min.) 
for Anthisan. In view of the similarity of the figures derived from these two different types 
of experiment it is difficult to escape the conclusion that both the absolute and the relative 
durations of action of these two drugs are dependent mainly upon their duration of fixation 
by the tissues on which they act rather than upon, for example, differences in their rates 
of excretion. Some antihistaminics, however, give markedly discrepant results in the two 
types of experiment, indicating that such a view is not generally applicable to this class of 
drugs. Thus some may show a moderate half -action time when administered by mouth, 
and only a very short half -action time when administered locally. The most striking example 
is Benadryl, which has an oral half -action time somewhere between that for Antistin and 
that for Anthisan, but which, on local application (see fig. 5), has a half -action time of under 
30 minutes. In such instances, where the drugs are not firmly fixed by the tissues, their 
duration of action must presumably depend mainly on their duration of sojourn in an 
active form in the extracellular fluid and thus ultimately on their rate of inactivation, or of 
excretion, or both. 
The foregoing comparisons show clearly that histamine antagonists differ markedly in 
their relative potencies and durations of action. Thus Phenergan is about seven times more 
potent than Anthisan and about fifteen times more potent than Antistin : the time from full 
to half -action for Phenergan is about three and three- quarter times greater than that for 
Anthisan and over five and a half times greater than for Antistin. It is evident that both 
these factors must be taken into account in assessing the relative merits of both existing and 
proposed new histamine antagonists. 
A further important factor is, of course, the relationship of side -effects to antihistamine 
activity, for it is the side -effects which at present constitute one of the chief limiting factors 
in the usefulness of these drugs. We have discussed elsewhere (Bain, Hellier and Warin, 
1948; Bain, Broadbent and Warin, 1949) the difficulties associated with the assessment of the 
incidence and severity of side -effects, and have stated earlier in this paper that we have not 
dealt with these in a quantitative fashion. We hope, however, that it may be possible to 
devise a semi- quantitative treatment of side -effects by applying to them a system of "scoring ". 
The "scores" obtained in the same group of subjects by different drugs could then be used 
to derive a "Mean Side -Effect" or "Mean Toxicity Quotient ". Determined on equi- potent 
doses of different drugs this might indicate the relationship, if any, between the most interest- 
ing side -actions -those which are so similar to the effects of hyoscine -and the specific anti- 
histamine effect itself. But from the clinical point of view it would also be important to 
compare equi- therapeutic as distinct from equi- potent doses and this would clearly give a 
different quotient, the difference depending to a large extent on the relative durations of 
action of the drugs compared. This will be evident from the observations about to be 
described. 
Comparison of therapeutic potencies. -We have so far been able to make a therapeutic 
comparison of only two drugs -Phenergan and Anthisan. As details of this comparison 
Are presented elsewhere (Bain, Broadbent and Warin, 1949) only a summary will be given 
here. 
In 20 patients with chronic urticaria the reaction to intradermal test doses of histamine 
and, when present, the dermographic reactions to various stimuli, were measured by Dr. 
Warin before and at intervals after the institution of therapy with Anthisan, and compared 
with the progress of the urticaria. The Anthisan was given two, three, or four times a day, 
as was found necessary. After a rest period the control observations were repeated and the 
patients put on Phenergan. In view of the long duration of action of this drug it was given 
in a single dose at night. Given in this way we hoped that the drowsiness which it often 
causes would but contribute to sleep and that any other side -actions would pass unnoticed, 
whereas the antihistamine effect would continue throughout the following day. An attempt 
was made to adjust the dose of Phenergan so as to give the same therapeutic effect as with 
Anthisan in the earlier period of treatment: we hoped to be able in this way to establish the 
approximately equivalent therapeutic doses. 
While Anthisan had usually to be given three or four times a day the nightly dose of Phenergan 
controlled the urticaria in all the patients throughout twenty -four hours. Only 3 patients were 
completely free from side -effects with Anthisan against fourteen on the nightly dose of Phenergan. 
The only side -effect noticed with Phenergan was morning drowsiness, but in only 5 patients did this 
persist throughout treatment. 14 patients preferred Phenergan, 5 had no preference and only one 
28 
preferred Anthisan ; the high preference for Phenergan was clearly based on the relative absence 
of side- actions with this drug. Thus with Phenergan in nightly doses the appreciated incidence of 
side -effects, and the severity of these when they occur, is much less than with equi- therapeutic doses 
of Anthisan given, as it usually has to be, several times a day : hence it should be possible to obtain 
adequate therapeutic effects by easily tolerated nightly doses of Phenergan in patients unable to 
tolerate the necessary divided doses of Anthisan. 
A diagrammatic representation of the type of data obtained from some of the patients is 
given in fig. 6. In this case it is evident that the effect of 50 mg. Phenergan lies between that 
for 600 and for 900 mg. per day of Anthisan. In making the quantitative therapeutic com- 
parison, however, 10 cases have had to be excluded; 8 because the dose of Phenergan used 
produced a greater therapeutic effect than did the Anthisan in the earlier period of treatment; 
and 2 because in them the urticaria was not abolished. In the remaining 10 cases the thera- 
peutic effect of a given dose of Phenergan was produced by a total daily dose of Anthisan 
from eight to eighteen times greater: the average figure was fourteen. Thus, on the average, 
25 mg. Phenergan per day is the approximate therapeutic equivalent of 350 mg. Anthisan 
per day, or of three divided doses each of about 115 mg. Similarly, a nightly dose of 50 mg. 
Phenergan is the equivalent of about 700 mg. Anthisan per day, or of three divided doses 
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FIG. 6. -To show the type of result obtainable in the clinical comparison of histamine antagonists. 
Subject W. H., male, aged 23, urticaria present for two years, associated with dermographism. 
Urticaria: +, occasional wheal; -E-+, a few wheals; +-I-+, moderate number of wheals. Side - 
effects: +, slight symptoms on questioning; + +, complaint of mild symptoms; + + +, complaint 
of moderate symptoms. Mean diameter of wheals (thick lines) and flares (thin lines) in cm. 
Histamine reaction from 0.05 ml. of 0.0l % w/v histamine acid phosphate. Dermographic reaction 
from various traumatizing stimuli (mean of 4 measurements). In this subject 50 mg. Phenergan per 
day had an effect between that of 600 and that of 900 mg. of Anthisan per day. 
With such a relationship between these dose values it is perhaps justifiable to express the 
relative therapeutic potencies of Phenergan and Anthisan -and, when the information is 
available, of Phenergan and any other histamine antagonist -in terms of the average ratio 
between the equi- effective twenty -four hour doses. This ''therapeutic ratio" cannot be so 
called because of the varied connotations which already attach to the expression, and we 
propose the clumsier "Mean Therapeutic Quotient" or M.T.Q. This can be regarded as 
stating in respect of the total dose in twenty -four hours, (1) how much more powerful 
Phenergan is than the drug with which it is compared, or (2) by how much, on the average, 
a given dose of Phenergan must be multiplied to find the daily dose of the other drug likely 
to produce the same therapeutic effect as the Phenergan. 
The M.T.Q. of Anthisan is about 14. Thus while Phenergan is only about seven times more 
potent than Anthisan when compared in terms of the single doses required to produce the 
same intensity of effect (M.P.Q.), it is almost fourteen times more potent than Anthisan 
when compared in terms of the relative doses per day required to maintain a similar level of 
antihistamine activity (M.T.Q.). It is clearly the difference in the duration of action of the 
two drugs, expressed as the Mean Duration Quotient, which is the main factor determining 
the difference between the mean potency and mean therapeutic quotients. 
Concluding remarks. -The differences so far noted among the various drugs are differences 
of degree. But in our first experiment on the duration of action of Phenergan (illustrated in 
fig. 2) the initial effect of the drug was to potentiate the intradermal histamine response in 
all four subjects. In subsequent experiments this phenomenon was seen only in some subjects, 
and the mean curve did not fall below the zero abscissa. These different results are indicated 
in fig: 4, where alternative routes for the onset of the antihistamine effect of Phenergan are 
indicated by broken lines. (No other histamine antagonism has exhibited this effect, with the 
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possible exception of Antistin: but with this the only evidence was indirect -the somewhat 
late rise of the curve (see fig. 2) from the zero line.) A similar potentiation of the intradermal 
histamine response has often been noticed -but again only in some subjects -when Phenergan 
and histamine have been injected to the skin in experiments of the kind illustrated in fig. 5. 
The effect was most commonly seen when the two drugs were administered simultaneously. 
We sought to account for this phenomenon by the hypothesis that Phenergan might 
antagonize histaminase. Some support is perhaps given to this view by the work of Kapeller- 
Adler (1949) who has shown that Phenergan and Antistin inhibit the action of histaminase 
in vitro, but that none of the other histamine antagonists investigated do so. 
If the primary potentiation of the intradermal histamine response with Phenergan is due 
to partial inhibition of histaminase then it is clear that the fixation of the drug by the enzyme 
occurs very quickly, in marked contrast to the rate of fixation by the capillaries. But to what 
total extent histaminase may be inactivated by therapeutic doses of Phenergan, or how long 
the effect may persist, it is impossible from our experiments to say, because the effect itself, 
manifested by the potentiation of the wheal response, becomes quickly masked by the 
establishment of the specific antihistamine action of the drug. However, if Phenergan is 
potent as an inhibitor of histaminase it is possible that therapeutic doses of the drug in persons 
relatively resistant to the antihistamine effects might produce an exacerbation of any symp- 
toms due to histamine release; such untoward effects could presumably be countered by 
increasing the dose. 
It is generally assumed that histamine antagonists act by receptor competition -that they 
become fixed, in varying degree and with varying firmness, to receptors on the tissues on 
which histamine acts, and, by this preferential fixation or competition, partially exclude 
or block the access of histamine to these receptors (Gaddum, 1948). The failure of histamine 
antagonists to diminish histamine- induced gastric secretion may be due to a difference in 
the histamine receptors in the gastric glands such that the antagonists fail to become fixed 
to them. Of the actions of histamine which are influenced by histamine antagonists those 
due to injected (exogenous) histamine are usually held to be more readily affected than 
those due to histamine released by the tissues (endogenous histamine). Furthermore, Dale 
(1948) distinguishes between histamine which is released by the cell on which it reacts and 
that which when released upon he calls 
intrinsic and the latter extrinsic histamine. In man the antihistamine drugs are usually 
much less effective against intrinsic than against extrinsic actions of endogenous histamine. 
They are -assuming the role of histamine in these conditions -less effective, for example, 
in bronchial asthma, where the histamine is liberated by the reacting structure, than in 
chronic urticaria where it is not. But it may be that the relative failure of histamine 
antagonists to block intrinsic actions is due simply to the difficulty, with the agents at 
present available, of reaching an effective drug level at the site of histamine release with 
doses of the drugs which are tolerable. In chronic urticaria, on the other hand, the hista- 
mine does not act upon the cells from which it is liberated but upon the capillaries with 
which it subsequently comes in contact through humoral channels. Histamine antagonists 
are thus regarded as effective in urticaria because the liberated histamine acts in a fashion 
analogous to that of histamine injected from outside. 
Nevertheless it may be wondered how antihistamine drugs can abolish urticaria when, 
according to the pharmacological data summarized earlier in this paper, very large doses may 
be required to produce a 70 % reduction in the intradermal histamine wheal response and 
quite intolerable doses are theoretically required to abolish it. Nor is it only when histamine 
antagonists are administered orally that we have failed to abolish the intradermal histamine 
response, for we have failed equally to do so when the drugs are administered locally to the 
skin. The average maximum percentage reduction obtained by local administration, even 
of Phenergan, was about 60 % (see fig. 5) and the maximum individual reductions seldom 
exceeded 80 %. 
Chronic urticaria is in fact abolished, however, when the area of the intradermal 
wheal response is reduced by, on the average, about 50 % with a range of individual values 
from 30 % to about 80 %. On the other hand, the average percentage reduction 
in the dermographic wheal response at the stage when urticaria is cleared is of 
the order of 90% (range 86-96%). This type of difference is illustrated in fig. 6 
where, with the 50 mg. dose of Phenergan, the dermographic wheal response is 
reduced by about 90 % and the intradermal histamine wheal response by 70 %. 
Unfortunately we have but few observations of this kind on the dermographic response. 
Nevertheless if this sort of result can be confirmed and the quantitative differences 
between the effects of the drugs on injected and on liberated histamine respectively can be 
shown not to be due to the different circumstances attending the production of the two 
types of reaction, then it will be difficult to escape the conclusion that, in the relief of 
chronic urticaria the histamine antagonists may be exhibiting a dual modality of action- 
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by antagonizing the action of histamine on the capillaries, by a receptor competition 
mechanism, on the one hand, and by diminishing the release of histamine from the 
tissues, by some unknown mechanism, on the other. We have evidence, indeed, from other 
lines of work that histamine antagonists may in certain circumstances act in this latter fashion. 
But much further work is needed before any discussion of the various possibilities concerning 
the mode of action of histamine antagonists can be justified on the basis of experimental 
work on man; the view just expressed is therefore to be regarded as little more than a 
speculation. 
SUMMARY 
(1) Methods of comparing the weight- for -weight potencies, relative durations of action, and relative 
therapeutic efficacies of histamine antagonists are described, but statistical treatment of the data is 
omitted. 
(2) The outstanding potency and duration of action of Phenergan (3277 R.P.) suggests its suitability 
as a standard against which these properties of the others can be compared. 
(3) Relative weight- for -weight potencies are expressed in terms of the "Mean Potency Quotient" 
obtained by dividing the mean dose of the drug under test which produces a given mean antihistamine 
effect, by the mean dose of Phenergan which produces the same effect. The quotient states how much 
more powerful Phenergan is than the drug with which it is compared, or by how much the dose of 
the drug under test must be multiplied to give the same effect as a given dose of Phenergan. The 
M.P.Q. of Anthisan is about 7 and of Antistin about 15. 
(4) Relative durations of action are expressed in terms of the "Mean Duration Quotient ", 
obtained by dividing the time from maximum to half -maximum action for Phenergan by the cor- 
responding time for an approximately equi- effective 'dose of the drug under test. This expresses the 
half -action time for Phenergan as a multiple of the half -action time of the drug with which it is 
compared. The M.D.Q. of Anthisan is 3.8 and of Antistin 5.6. 
(5) Relative therapeutic efficacies in chronic urticaria may be expressed in terms of the ` ` Mean 
Therapeutic Quotient ", obtained by dividing the daily dose of the drug under test by the daily dose 
of Phenergan required to produce an equal therapeutic response. This expresses the therapeutic 
potency of Phenergan as a multiple of the potency of the drug with which it is compared, or states 
by how much the daily dose of Phenergan must be multiplied to give the equivalent daily dose of the 
other drug. The M.T.Q. of Anthisan in chronic urticaria is about 14. 
(6) A possible qualitative difference between Phenergan and the other drugs is noted, and some 
aspects of the probable mode of action of histamine antagonists are briefly discussed. 
The cost of this work was met by a grant from the Medical Research Council. 
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The Evaluation of Drugs in Man, with Special 
Reference to Antihistaminics 
BY W. A. BAIN 
THE evaluation of drugs in man involves essentially the application to man of those principles 
of quantitative pharmacological investigation that have hitherto been applied chiefly to 
biological assay and standardisation procedures on animals and isolated animal tissues. 
It was, indeed, largely for the solution of the problems of biological standardisation that 
these methods were first developed. In general they are methods that permit, among other 
things, the establishment of dosage - response relationships. 
The pharmacologist has two different types of data that can be used for the determination 
of such relationships. The first is got by measuring the degree of effect produced by a drug 
(graded or quantitative response), the second by noting the presence or absence of a drug 
effect ( "all or none" or quantal response). Both are important. The quantitative method 
is capable of yielding much more information than the other and is preferable when it can 
be applied. It has the further advantage that, if the same subjects are used for all the 
comparisons, only small numbers need be used. The quantal method, besides yielding less 
information, involves larger numbers of subjècts. In man, however, because of subjective 
or other effects that can be arbitrarily graded, responses that would be quantal in animals 
can often be made to yield data that are essentially quantitative and can be dealt with as 
such. Further, there is usually more than one effect or manifestation of a particular drug 
that can be recognised and may be of importance in man : consequently, even when the 
different effects are strictly "all or none," there is more information to be extracted from 
the quantal type of response in man than from the corresponding type in animals. 
It seems that the future advancement both of human pharmacology itself and of rational 
pharmacotherapeutics must depend largely on how far such methods can be developed and 
applied to the investigation of drug actions in man. The extent to which they can be 
developed will itself depend largely on the success achieved in recognising or establishing 
measurable criteria of the effects of the drug under test. 
Within a class of drugs the short -term evaluation in man should involve not only the 
determination of relative weight for weight potencies when the drugs are administered by 
their usual routes, but also the determination of relative rates of onset and duration of action 
and the relative immediate toxicities, This pharmacological evaluation can sometimes be 
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carried out on normal people, but at other times only on patients suffering from some particular 
condition. In either event, since the object of obtaining the pharmacological information 
is to make possible its rational application in pharmacotherapeutics, a therapeutic evaluation 
of the most promising drugs of the class should succeed the pharmacological one. Often, 
however, the pharmacological evaluation on patients will constitute, by its nature, the 
short -term therapeutic evaluation as well. 
Quantitative comparisons of drugs in man are subject to the same variables as are 
comparisons in animals and animal tissues, but additional difficulties and limiting factors 
immediately present themselves. Thus, in obtaining dosage - response data in animal 
experiments, an objective record of the whole effect of a given dose can often be obtained, 
leaving no doubt about the maximum effect. Even where no objective record is possible, 
the number of observations yielding the required data for a given dose can be made sufficiently 
great to give a smooth curve of response. Such curves are clearly necessary for dosage - 
response data in man and to determine differences in duration of action of different drugs, 
but continuous and objective records of the drug effect can seldom be obtained, and the 
number of observations that can be made to determine the' rise and fall of the effect is limited. 
Further, the dose -range used in animals can be as great as desired, but is necessarily limited 
in man. The element of personal danger is never entirely absent in human experiments, and 
particular caution has to be exercised in investigating new or hitherto untried compounds. 
Finally, since only small numbers of subjects are usually available for such tests, all com- 
parisons have to be made on the same people, who, if the experiments are numerous and of 
long duration, begin, sooner or later, to find them exceedingly tedious. 
The illustrations in this paper are simple examples of the application of a graded response 
method to the comparison of antihistaminics in man. 
The antihistaminics are drugs of varied structure, whose most important action is to 
antagonise, presumably by receptor competition, certain of the actions of histamine. Most 
antihistaminics have other actions, such as the hyoscine -like effects (both central and 
peripheral) seen on systemic administration and the anaesthetic effects produced by local 
application to suitable sites and lesions. The hyoscine -like effects, while sometimes useful 
therapeutically, more often constitute the most undesirable side -action of the drugs. 
Since histamine itself, injected into the skin, gives characteristic effects -the wheal 
and the flare -that can be measured, the quantitative modification of either or both of these 
effects by antihistaminics can be used as the basis for an evaluation and comparison of different 
antihistaminic drugs in man. 
The techniques used in our original experiments have been published1,2 and need not 
be detailed here. Three drugs, promethazine, mepyramine and antazoline, were compared 
for relative potencies and durations of action, and the first two for their therapeutic efficacies. 
Comparisons of potency were made by determining, for each drug, under standard conditions, 
the maximum reduction of the intradermal histamine response in each of a group of six 
subjects to three different oral doses of the drug. The average maximum response to each 
dose of each drug was expressed as the average percentage reduction of wheal area. As 
the dose - response curves for the three drugs were parallel, a simple ratio expressed the 
potency differences. Promethazine was about seven times more potent, weight for weight, 
than mepyramine and about fifteen times more potent than antazoline. 
Relative durations of action were determined by following the reduction of the effect 
of an intradermal dose of histamine, usually 3 µg, to and beyond its maximum after adminis- 
tering approximately equi- effective doses of the different antihistamine drugs to another 
group of subjects. Relative durations of action were expressed as the average times taken 
for the full effect of the drug to be reduced to half. For promethazine, mepyramine and 
antazoline these times were 19f, 5f and 3jti hours respectively. A therapeutic comparison 
of promethazine and mepyramine was then carried out on 20 patients with chronic urticaria. 
All these had first been treated with mepyramine and the daily dose to control the urticaria 
was determined. They were then taken_ off all therapy and, when the reactions to intradermal 
histamine had returned to normal, treated with promethazine. This drug, in view of its 
long duration of action, was given in a single dose at night, the dose being adjusted to give as 
nearly as possible the same effect as the mepyramine in the earlier period of treatment. 
The results showed that promethazine was, on the average, about fourteen times more potent 
therapeutically than mepyramine. In the pharmacological tests it was about seven times 
more potent. It is clearly to the prolonged duration of action of promethazine that this 
33 
difference between the pharmacological and therapeutic potencies was due. A further 
point brought out by this comparison was that the effective dose of promethazine produced 
fewer side reactions than the corresponding dose of mepyramine, so that 14 of the 20 patients 
preferred the promethazine treatment. 
These first comparisons of potency and duration of action were made in separate experi- 
ments on different groups of people. The necessity for reducing the total number of 
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Fig. 1. Graphical representation of time - response data for compound "405" . and chlor- 
prophenpyridamine. Left -hand family of curves, effects of 12.5. 25 and 50 mg of "405" ; right -hand 
curves, 12.5, 25 and 50 mg of chlorprophenpyridamine. Points of maximum action and of half -action 
are indicated on the graphs 
information is obtained simultaneously from the same subjects. Each subject receives 
duplicate or triplicate intracutaneous injections of 3.0 pg of histamine, estimated as base, 
in 0.05 ml, and the resulting wheal areas . are recorded 5 to 7 minutes later. The anti- 
histaminic is then taken on an empty stomach. The test dose of histamine is injected half- 
hourly until the maximum effect has been reached, and then hourly or at longer intervals, 
until the effect has obviously passed its half maximum. By plotting the percentage reduction 
of wheal area against time for each subject, an approximate curve of action for the dose of 
the drug in each subject is determined. From each such curve is derived an estimate of the 
maximum effect, the time for the establishment of this and the time for it to be reduced to 
half. The individual results in the group are averaged. Three different doses of each drug 
are usually investigated. 
Table I gives the main data abstracted from nine experiments of this kind on three 
different drugs. A graphic representation of the results with two of these, chlorprophen- 
pyridamine, and a compound prepared by Dr. Adamson of the Wellcome Laboratories 
and known as "405," is shown in Fig. 1. The comparison of these drugs is of particular 
interest, as they both have the same potency but differ in the rate at which the maximum 
effect is reached and, more important, in the rate at which it falls to half. Compound "405" 
thus seems an exception to the general rule that the more potent an antihistaminic the longer 
its duration of action. 
The averages of the individual maximum percentage reductions of wheal area for each 
dose of an antihistaminic (see Table I) constitute the data from which dose - response 
relationships are Obtained. Fig. 2 shows such relationships for some drugs, derived in this 
TABLE I 
SUMMARY OF DATA ON RELATIVE POTENCIES AND DURATIONS OF ACTION 





Times to maximum and to half -maximum action 
Average of individual 
half- action times, 
i.e., time to half- 
Average time 
for all doses Average half - 
reductions action less time to maximum action time 
Drug Dose, + S.D. to maximum action, action for all doses 
mg minutes 
Chlorcyclizine 25.0 23.2 + 2.4 932 - 348 = 584 294 minutes 1024 minutes 
100.0 44.3 + 2.7 1082 - 278 = 804 (5 hours) (17 hours) 
250.0 57.9 + 2.3 1940 - 255 = 1685 
Chlorprophenpyri- 12.5 36.0 + 4.5 1600 - 190 = 1410 187 minutes 2050 minutes 
damine 25.0 48.3 + 2.1 2640 - 188 = 2452 (3 hours) (34 hours) 
50.0 56.7 + 1.7 2470 - 183 = 2287 
"405" 12.5 39.1 + 1.75 760 - 120 = 640 122 minutes 679 minutes 
25.0 46.6 + 2.66 863 - 128 = 735 (2 hours) (11f hours) 
50.0 55.8 + 2.36 779 - 117 = 662 
way from a group of six people. The slopes of the lines are less than in our original experi- 
ments on other subjects and are such that if the dose to produce a 30 per cent. reduction 
in the response is taken as unity, then for a 65 per cent. reduction it is ten, and, assuming the 
lines to maintain their courses indefinitely, the dose to abolish the effect of 3µg of histamine 
is approximately 100, i.e., about 1.5 g of promethazine or 10.0 g of mepyramine! (The 
doses of the different drugs required to produce a 30 per cent. response are indicated below 
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Fig. 2. Dose - response relationships for different antihistaminics. The dose of each pro- 
ducing a 30 per cent. reduction in wheal area is shown below the abscissa; these indicate relative 
potencies. Thus, taking promethazine as 1, the corresponding doses required to produce the same 
maximum effect are: chlorprophenpyridamine (and "405 ") f, chlorcyclizine 2f, mepyramine 6f, 
antazoline 141, thonzylamine 20 
O 
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It is clearly impossible to abolish the effects of a 3 -µg intracutaneous test dose of histamine 
with any of the antihistaminics at present available. Equally clearly, it is possible to prevent 
or abolish many of the effects of histamine liberated in the body by doses of these drugs 
that produce only a moderate reduction in the response to the 3 -µg intracutaneous test dose. 
Clinical experience, indeed, especially with the longer acting drugs, indicates that the 
symptoms of some allergic conditions, e.g., hay fever, can be controlled by a level of anti- 
histaminic effect represented by no more than a 10 or 15 per cent. reduction of the 3 -µg 
test wheal. How, then, can these percentage reductions of wheal area be interpreted so as 
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Fig. 3. Shift of dose - response curve for intracutaneous histamine by an antihistaminic. 
Experiment on five subjects. Upper line before and lower line after dosage of antihistaminic. 
Assuming the regressions are parallel, ,the shift shown, representing a 25 per cent. reduction 
of the 3 -µg test wheal, involves a six -fold increase in the dose required to produce any given effect. 
For further explanation see text 
As the percentage reduction of wheal area that we measure is an expression of the shift 
of the dose - response curve to intracutaneous histamine, the following considerations provide 
a possible answer. The upper graph in Fig. 3 shows the log -dose - response regression for 
intracutaneous histamine in five of the subjects used in the foregoing experiments. The 
lower graph shows the shift of this 3 hours after ingestion of an antihistaminic. If it is assumed 
that the two regressions are parallel, the shift is such that a six -fold increase in dose is now 
required to produce the same effect as originally. Now the percentage reduction of wheal 
area to the 3 -µg test dose in this experiment is about 25. Thus a 25 per cent. reduction 
of wheal area involves a six -fold increase in the dose of intracutaneous histamine required 
to produce any given original effect within the dose range represented on the graphs. By 
drawing parallel dose - response regressions through points representing different percentage 
reductions of the effect at the 3 -F.cg dose level, the relationship between the percentage reduction 
of wheal area to this test dose, and the extent to which any dose of intracutaneous histamine 
must be raised to produce its original effect, is immediately established. This relationship, 
calculated from Fig. 3, is shown by the lower line in Fig. 4. If the slope of the dose - response 
curve to intracutaneous histamine is shifted slightly, so as to meet the abscissa at 0.002 
instead of 0.0015 µg, the upper line of Fig. 4- results. Thus, though the exact relationship 
will depend on the slope of the dose - response regression, it is obvious that a relatively 
small percentage reduction in the intracutaneous wheal response represents a considerable 
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increase in the dose of histamine required to produce any given response, including a threshold 
response. 
Thus it is not difficult to see how the effects of extrinsic histamine liberated in the body 
may be prevented or abolished by doses of antihistaminics that produce only a moderate 
reduction in the effect of an intracutaneous test dose, for this relatively small reduction may 
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Fig. 4. Relationship between percentage reduction of wheal area from a 3 -pg 
test dose of histamine by an orally administered antihistaminic, and the extent to 
which the intracutaneous dose of histamine must then be increased to produce the 
same effect as originally. 
Ordinate: multiple of dose . of intracutaneous histamine (log scale). Abscissa: 
reduction of wheal area from 3 -µg intracutaneous test dose. Lower graph from 
data based on normal (upper) dose - response line in Fig. 3. Upper graph shows 
effect of modifying slope of normal dose - response line so that it cuts abscissa in 
Fig. 3 at 0.0015 instead of 0.002. Note that 10 per cent. reduction of wheal area 
more than doubles dose required to produce a given effect. Similarly, a 30 per cent. 
reduction involves a 9 to 10 -fold increase, a 60 per cent. reduction an 80 to 100 -fold 
increase and so on. For further explanation see text 
This affords one way of resolving what many clinicians regard as an impossible discrepancy 
between pharmacological experiments and clinical experience. 
In conclusion it should perhaps be pointed out that the methods very briefly outlined 
here, while probably capable of development to the same degree of precision as other quantita- 
tive biological methods, have been used simply as a better means than any other available 
of obtaining comparative information about . antihistaminics in man. But no undue stress 
should be placed on the numerical results.. Nor must it ever be forgotten how wide is the 
individual variation in response to these drugs4 and how necessary it is, in their clinical 
use, to take account of this. 
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TRIALS OF ANTIHISTAMINICS 
[TO //te EDITOR of the BRITISH MEDICAI. JOIJRNALI 
SIR, -Like Dr. H. Herxheimer (July 26, p. 228) I have a 
little experience with antihistaminics and, like him, too, 
thought it unfortunate that so much ingenuity and time 
should have been spent ont a project (Sevitt et al., July 12, 
p. 57) that did not and could not decide the question at issue. 
But I would like to go further than Dr. Herxheimer and 
make some remarks of a general kind about trials of anti- 
histaminics- remarks that seem the more called for by 
reason of the very wide range of potencies possessed by the 
different drugs in this group, and the seeming unwillingness 
of people to take account 6f this. 
It is, of course, desirable that any therapeutic trial should 
be well designed and executed and the data properly assessed 
and interpreted. While much more care is usually given to 
these matters now than formerly, there are two defects that 
may sometimes be evident in otherwise irreproachable trials. 
The first is a failure to state precisely the question that the 
trial is set to answer. The second is that the answer itself - 
especially if it is a negative one -instead of being set forth 
as a particular proposition, is often given a general form that 
is quite unwarranted. (And even if the investigator makes 
neither of these mistakes he may be misquoted by others 
and so made to seem guilty of one or both of them.) 
Thus in a trial with a given antihistaminic a very relevant 
part of the question that should be posed at the outset is : 
" Does drug X (in dose 'y, n times a day) affect the course 
of the condition ? " And the most that the answer could 
show would be whether this seemed to be so or not. To 
generalize from the outcome of a single trial with one drug 
to the class of antihistaminics as a whole is of questionable 
validity when the results are highly favourable, but utterly 
indefensible -if the drug seems to be of no value at all. 
In a trial to test whether antihistamine action per se is 
of benefit in any particular condition a primary essential is 
to make sure that the drug chosen, its dose, and the spacing 
of this are such as will in fact produce an antihistamine 
effect (and, one might add, that the effect is maintained 
and is of adequate degree). There is little doubt that in 
some otherwise excellent trials this elementary condition has 
not been fulfilled. When the results of such trials are nega- 
tive they are valueless, and if expressed in a general form 
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they are misleading as well. Indeed, the only negative 
evidence that would seem to justify a general negative con- 
clusion would be that from several trials in each of which it 
was unquestionable that the drugs had been used in effective 
doses. . 
Nor is there much excuse to -day for investigators failing 
to use effective drugs in effective doses. Pharmacologists 
have gone to some trouble to determine, in man, the relative 
potencies and durations of action of different antihistaminics. 
This information is readily accessible, and it seems a pity 
that it should so often be ignored -especially when this may' 
lead to the unwitting choice of the weakest available drug 
for an extensive and painstaking trial. 
If antihistaminics are to be tested in a condition not known 
to respond to them, then, even if the available pharmaco- 
logical information is appreciated and used, it is surely a 
good plan to find out by a preliminary or pilot trial whether 
a large -scale rigorous trial is likely to be worth while. If 
a small pilot trial, using one or more potent drugs in 
adequate doses, gives no evidence whatever of any benefit 
from the treatment, it is probably fair to say that an exten- 
sive rigorous trial is not worth while. If, on the other 
hand, the results of the pilot investigation are obviously 
favourable, then some of the best conditions applicable to 
the rigorous trial are already known, and others can be 
determined by further pilot observations, with consequent 
saving of time and effort in the design, conduct, and assess- 
ment of the main trial. It seems remarkable that pilot trials 
are not more popular, for their utility and value as a means 
of getting information that can be used in a large trial are 
often very great. 
These various points may, indeed, be obvious ones ; but 
they all seem, at one time or another, to have escaped the 
notice of some workers on antihistaminics, and so no 
apology is needed for drawing attention to them. -I am, etc., 
Department of Pharmacology, Leeds. W. A. BAIN. 
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PILOT TRIAL OF AN ANTIHISTAMINIC DRUG IN 
THE CONTROL OF "TETRYL" DERMATITIS 
By W.A. Bain and Grizel H. Thomson 
(From the Department of Pharmacology, University 
of Leeds, and a Royal Ordnance Factory) 
The compound 2:4 :6 trinitrophenylmethylnitramine, 
known commercially as "Tetryl ", and in the services as 
C.E. (Composition Exploding), is an important inter- 
mediate detonating agent for high explosive charges. 
It has long been known that workers with "tetryl ", in 
addition to becoming yellow about the hands and face, 
are prone to develop dermatitis and respiratory 
troubles (Smith, 1916; Cripps, 1917; xuxton, 1917). 
When contact with "tetryl" is heavy, and workers are 
new to the job, the incidence of dermatitis is high - 
however carefully the workers are selected, and how- 
ever stringent the application of preventive measures, 
such as protective clothing, barrier creams and the 
like. Of new people who go into training for work in 
heavy contact with "tetryl" only a small proportion 
completes the course and is available for production: 
of this a high proportion leaves work at the first 
onset of symptoms, - or even from fear of the substance, 
and what it may do to them. 
Heavy contact is suffered by those who press. 
"tetryl" into pellets. The labour problem presented 
by this type of work is illustrated by Table I, which 
shows. the turnover of trained pressworkers in a 6 -month 
-2- 
period prior to the trial, together with an analysis 
of the reasons for the high rate of loss, 
TABLE I. 
LABOUR TURNOVER OF ' TETRYL' PRESSWORKERS 
IN A 6 -MONTH PERIOD PRIOR TO THE TRIAL. 
Total trained and entering presswork 
Number on presswork at end of period 
Number lost to presswork by end of period 
Reasons for losa of pressworkers :- 
PERSONAL - staining of skin; fear of illhealth, 
including dermatitis; incipient 
dermatitis; other factors - 
MEDICAL - removed from presswork by medical 
officer for dermatitis or other 
medical reasons - 
PRODUCTION - transferred by Production Dept. 








It is clear from the table that, apart from 
transfers to other jobs by the Production Department, 
workers lost to the presses fall into two main cate- 
gories. In the first are those who leave, often on 
very slight provocation, for personal reasons, - 
because of staining of the skin and clothing, the fear 
of skin trouble, the onset of symptoms of skin trouble, 
the respiratory irritation caused by "tetryl" dust, 
and other factors: these are the people who will not 
tolerate in peacetime the discomforts that they might 
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endure or ignore in time of war. In the second 
category - lost for medical reasons - are those willing 
to suffer discomfort, often of considerable degree, and 
who are only removed from heavy contact on the direct- 
ion of the medical officer. 
This high wastage of labour makes it difficult to 
maintain an adequate number of pressworkers. Any safe 
and effective means of treating or preventing the skin 
condition would not only reduce the losses from derma- 
titis itself but would be likely to lessen or abolish 
the fear of it and thus lower the losses from 
"personal" reasons. 
Without going into detail it may be said that the 
dermatitis develops after 8 - 15 dayst contact with 
"tetryl ", and that people who have recovered from an 
attack can often return to a lesser, or, less commonly, 
to the same degree of contact, without developing 
further symptoms. Such are said to have "salted ". 
Those who do not develop dermatitis at all - some ten 
per cent or less of those in heavy contact - are said 
to be "naturally immune" or "naturally salted ". 
Theoretical basis of trial. 
As the premonitory symptoms are usually either 
itching of the face and neck - progressing to erythema 
and urticaria - or rhinitis with respiratory discomfort 
suggestive of mild asthma, it looked as if the onset of 
the condition was associated with the release of hista- 
mine. The fully developed dermatitis might thus be 
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the end result of a process in which such release 
played an important part. It might result from a 
sensitisation reaction to "tetryl" such as has been 
suggested by Gell (1944); or, alternatively, from 
"tetryl" acting as a simple histamine liberator. In 
either event it seemed possible that if adequate doses 
of a suitable antihistaminic were given by mouth, at a 
sufficiently early stage, the symptoms or signs might 
be modified or suppressed and "salting" occur - whether 
due to desensitisation in the strict sense, or to 
depletion of skin histamine, or both, - without the 
development of a frank and disabling dermatitis. 
In view of the accident risk in work with "tetryl ", 
and the known side -effects of antihistaminics that 
might well aggravate this, it was clear that before any 
large -scale controlled trial could be justified a 
preliminary or pilot trial would have to be conducted, 
in which the medical officer in charge knew exactly 
what was being given, and in what dose, and could be on 
the look -out for the sort of actions that might lower 
the standard of safety precautions. A pilot trial 
would show not only whether, on the basis of the thera- 
peutic results, a large-scale trial was likely to be 
worth while, but it would also provide information of 
various kinds that would be useful in the design and 
conduct of a rigorous trial - as, for example, the 
drugs, and the doses of these, likely to be both safe 
and effective; the most satisfactory stage at which 
-5- 
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begin therapy; how long treatment should continue; 
and so on. It is such a pilot trial that is described 
ere, in the belief that it affords a case for a 
rigorous controlled trial. 
lan and Conduct of Trial 
Because of the small numbers available for test 
and the necessity of getting as much information as 
ossible in the shortest time, - and for other reasons 
that need not be detailed - simultaneous controls were 
uled out. It was therefore necessary to compare the 
. Jesuits of the new treatment with those got by orthodox 
standard ") methods in a period immediately preceding 
he trial. This defect in design is not so serious as 
t might seem, for a great deal of information was 
available about the incidence of dermatitis in press- 
orkers and the results of "standard" treatment, so 
hat if the results of the new treatment did not show 
dramatic improvement over those of the old then the 
utter would obviously not be worth pursuing. A 
urther defect of the trial, but a necessary one in 
iew of the information wanted, was that the exp eri- 
ental treatment was started at various stages in 
ifferent groups of subjects - sometimes when derma - 
itis was evident, and even severe; sometimes when 
my itching or erythema was present; and sometimes at 
he stage - usually preceding the itching - when respi- 
ratory trouble was first noticed. In the analysis of 
the results these differences have been ignored, though 
-6- 
the results themselves made it evident, as was to be 
expected, that the earlier treatment was started the 
better. 
A careful and full record of the history and 
progress of each subject was kept. This involved the 
day to day recording of all information that could 
conceivably be relevant to the assessment and inter- 
pretation of the results. The collection of this 
information, by the medical and the training or produc- 
tion staff, was an onerous task; but, since no indi- 
cation of how the data would be treated was divulged 
until after the end of the trial there was thus intro- 
duced into the final grouping of results an element of 
objectivity that might otherwise have been lacking. 
Though the records of the trial are extensive and 
complex the results are presented here in as simple a 
way as possible. 
On all grounds it seemed desirable to use a 
powerful and long- acting drug in doses as low as were 
likely to be effective. A single dose at night was 
regarded as the ideal, with, if necessary, a smaller 
"boosting" dose of the same drug in the morning. In 
this way the maximum antihistaminic level would be 
reached during the night, and side effects be absent 
or minimal the next day (Bain et al., 1949). But 
should the antihistamine effect fall too low during the 
day it would be maintained by the smaller morning dose, 
which would be unlikely, by itself, to produce side 
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effects. This method of dosing was essentially a 
safety precaution, with which it was often possible to 
dispense once the reactivity of an individual to the 
drug had been determined. 
TAD drugs with the necessary potencies and 
durations of action were available - Promethazine 
Hydrochloride B.P. and Chlorcyclizine Hydrochloride 
A.N. (Bain 1949, 1951). But only a few observations 
were made with Promethazine, and these have not been 
included here. Chlorcyclizine is d1-1-(2,-chlorobenz- 
hydryl)-4-methylpiperazine monohydrochloride, and the 
preparation used was "Histantin" (B.W & Co.). The 
original dosage scheme was 50 mg at night, followed, if 
necessary, by 25 mg the following morning. In view of 
the known variation in the response to antihistaminics 
(Bain et al., 1948) it was appreciated that the doses 
used would have to be adjusted to individual needs. 
This was accordingly done when necessary - but only 
after it was clearly safe to do so. Thus though the 
doses used were at first small, they were increased, as 
confidence in the safety of the procedure was establi- 
shed, to a maximum, in one or two cases, of 300 mg per 
day. It is still possible, of course, that some of 
the failures in the trial had inadequate doses, or did 
not take the full amount of the drug provided. 
The possibility of having to use ephedrine or 
amphetamine sulphate to control sleepiness during the 
first day or two of chlorcyclizine treatment was 
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envisaged from the start, but this was seldom neces- 
sary: these symp athomimetic drugs, however, seemed 
more effective than the antihistaminic in controlling 
the respiratory symptoms associated with or premonitory 
to the dermatitis, and so were sometimes used along 
with the antihistaminic mainly for this purpose. 
Though this constituted a further defect in the trial 
it afforded information of some interest for subsequent 
work. 
Before detailing the results it is desirable to 
describe the "standard" treatment used in the 
"control" group. This was started as soon as 
symptoms or signs developed, but most people who 
required it had to be removed from contact with 
"tetryl ", since otherwise the dermatitis progressed. 
Preparations for local application to the affected 
areas were given. For erythema, papular rashes, 
and all cases of oedema without vesiculation, this 
was a calamine and lead lotion:- 
Calamine Lotion 961 
Strong Solution of Lead Sub acetate 4 
For all cases with exudation, or marked vesicu- 
lation, the use of this was preceded by the appli- 
cation of a lead, zinc and starch lotion: - 
Strong Solution of Lead Sub acetate 5 
Zinc Oxide 2 5 
Starch 2 5 
Glycerine 1 25 
Water to 100 
For subacute erythema, and during the recovery stage 
following the use of the calamine or starch lotion, 

















or a special oily calamine lotion : - 
Calamine 5 
Liquid Paraffin 50 
Oleic Acid 
Wool Fat 1 
Solution of Calcium Hydroxide to 100 
5 
When sleep was disturbed by itching, Phenobarbitone 
(65 mg) was given at night. 
Very severe cases of oedema, with or without 
vesiculation, were retained at rest in the surgery, 
and the affected areas were treated first with 
saline compresses, and then with the calamine and 
lead, or the lead, zinc and starch lotion. 
These local applications were not witheld from 
patients in the antihistamine treated group if they 
wished to use them, or if the medical officer 
thought their use in any particular instance was 
desirable. But nobody on antihistaminic treatment 
was given phenobarbitone. 
RESULTS 
In the course of the trial twenty -eight patients 
had the antihistamine treatment and sixteen the 
"standard" treatment. 
When a medical criterion of success or failure of 
treatment is used, the results are distributed as in 
Table II. The successes in this table are the people 
actually or potentially available for continued work 
in heavy contact with "tetryl ". The failures are 
those who relapsed on return to presswork and so were 
removed from heavy contact by the medical officer. 
There were thus twenty -six successes out of twenty - 
eight in the antihistamine treated group, but only 
four out of sixteen in the "standard" treatment group. 
-lo- 
TABLE II. 
RESULTS OF TREATMENT ASSESSED ON A MEDICAL CRITERION: 
(Successes are people actually engaged on, or potenti- 
ally available for, presswork after treatment. 






Successes 26 4 
Failures 2 12 
Or, alternatively, of thirty successes from a medical 
point of view, twenty -six had received the new treat- 
ment and four the old; whereas of the fourteen 
failures only two had received the new treatment and 
twelve the old. The probability that such differences 
would occur by chance, in a rigorous experiment with 
random allocation of subjects to control and experi- 
mental groups respectively, is less than 0.001. 
As there is a labour and production problem 
deriving directly from the medical or therapeutic 
problem presented by "tetryl" dermatitis, it was of 
interest to assess the results entirely on a labour 
and production criterion. This is done in Table III, 
in which the first row of the preceding table is 
modified, by the subtraction of losses for personal 
or production reasons, or for medical reasons other 
than "tetryl" dermatitis, and so includes only those 
medical successes, in each treatment group, who 
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continued to work as pressmen. The lower row remains 
unchanged as it includes only the medical failures 
who, by definition, could not continue to act as 
pressmen. Thus of twenty -one men continuing at work 
on the presses, nineteen had received the new treat- 
ment and two the old, whereas of fourteen who could 
not, for medical reasons, return to the presses, only 
two had received the new treatment and twelve the old. 
T ABT.F III. 







as pressmen 19 2 
Unable to continue 
work as pressmen 2 12 
As before, the probability of such differences 
arising by chance in a rigorous experiment is less 
than 0.001. 
(Twelve further patients were treated under 
pilot trial conditions subsequent to the trial 
period. Two of these were failures. If the 
twelve results are added to the first column of 
Table II the figures there become 36 and 4 respec- 
tively. These forty people will be referred to 
later.) 
Though the aim of the pilot trial was to get 
evidence that would show whether a rigorous trial was 
likely to be worth while, the results set forth in 
Tables II and III might seem so overwhelmingly in 
favour of the antihistamine therapy as to make any 
-12- 
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further trial superfluous. But it cannot be suffici- 
ently stressed that the pilot trial suffered, by its 
very nature, and by some of the conditions and limi- 
tations necessarily imposed upon it, from defects of 
design and conduct, and from the liklihood of bias in 
the assessment and interpretation of the results, such 
as would make it quite unjustifiable to attribute the 
observed differences between the groups as due solely, 
or even mainly, to the differences in treatment. One 
factor, for example, that may have biassed the results 
in favour of antihistanine therapy was the greatly 
increased attention given by the medical officer to the 
people receiving this. And though those in the 
earlier control group, on "standard" treatment, had 
also an unusual amount of attention, this was not so 
great as in the antihistamine group, - nor was it 
reinforced by the swallowing of tablets. 
While only a rigorous trial, with random alloca- 
tion of subjects to "drug" and "control" groups 
respectively, could give reliable information on the 
contribution made by the drug itself, there can be no 
doubt that, in the circumstances of the present trial, 
people fared very much better with the new treatment 
than with the old - whatever factors may have been 
responsible for the difference. 
If, however, the antihistamine therapy is as 
advantageous as the four -fold tables seem to indicate, 
then one would expect other evidence of this to have 
-13- 
been revealed by the trial. This was so. The first 
important advantage was that while people had usually 
to be removed from contact with "tetryl" at an early 
stage of the "standard" treatment- for otherwise the 
dermatitis progressed - they could usually remain in 
full contact for the whole period of antihistaminic 
treatment - with consequent benefit to the worker in 
earnings, and to production in output and costs. The 
second main advantage was the speed with which the new 
treatment controlled symptoms and signs. Some of 
these differences are indicated, for comparable groups 
of subjects, in Table IV. 
The first column of the table describes each 
group of subjects: successes are those maintained 
in or returned to full contact; failures are those 
who relapsed on return to contact. The other 
columns, in order and for each group, give : - the 
average maximum degree of dermatitis experienced; 
the average number of days to control symptoms and 
signs respectively; the average daily dose df 
chlorcyclizine from the beginning of treatment to 
the clearing of symptoms or signs, whichever took 
the longer. Numerals in brackets indicate range 
of values. Further points of explanatior are 
these : - 
Degree of dermatitis. This was assessed, for each 
person, on the following five -point basis: 
1. Erythema and itching. 
2. Papular erythema, with or without itching. 
3. Oedema or vesiculation. 
4. Oedema plus vesiculation. 
5. Marked oedéma, vesiculation and exudation. 
People in stages i and 2 are liable to leave work 
for "personal" reasons. Stage 3 is that before 
which a keen worker would probably not report to 
the medical department. 
Average daily dose. This is calculated for each 
group from the average individual daily doses - that 
is, from the total drug ingested by each person, 




























































































































































































































































































































































































































































































































































































































































































indication of how the dose varied in individuals. 
But it may be said that while at the beginning of 
the trial, and at the start of treatment in each 
person, the dose was usually small, (25 -50 mg), it 
was increased if need be up to as much as 300 mg 
per day in some cases. 
The first row of Table Iv gives the data on 
fifteen patients who had "standard" treatment out of 
contact with "tetryl ", and only one of whom was 
successfully returned to full contact. (Two "poten- 
tial" successes in this group were transferred to 
other work.) The second row gives the corresponding 
information on fifteen patients who developed derma- 
titis of, on the average, slightly lesser degree than 
did the control series, but who had the new treatment 
while still in full contact and who were all sub- 
sequently maintained at presswork. While "standard" 
treatment out of contact cleared symptoms in seventeen 
days and signs in eighteen, the new treatment, - 
despite the continued contact with the offending 
agent, - cleared symptoms in under two days and signs 
in five. This is a remarkable difference between the 
two groups and affords additional presumptive evidence 
in favour of the chlorcyclizine therapy. 
Of the forty people treated under pilot trial 
conditions, - twenty -eight in the trial itself, and 
twelve subsequently, - dermatitis was sufficiently 
severe in eight of them to demand treatment out of 
contact. Four were classified as failures and four 
were successfully returned to full contact. The 
last two rows of Table IV show the contrast between 
53 
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these groups. The failures, though with more severe 
dermatitis than the control group with "standard" 
treatment, responded more rapidly, and were clear of 
symptoms in under ten days as against seventeen, and 
of signs in twelve as against eighteen. But the four 
successfully treated out of contact were free of 
symptoms in two and a half days and of signs in seven. 
Whether the failures might have been avoided by using 
larger doses of chlorcyclizine - or whether, indeed, 
these patients took all the drug supplied - cannot now, 
of course, be determined. It is noteworthy, however, 
that, in general, symptoms were controlled much earlier 
than signs by successful antihistamine therapy - in 
contrast to What happened with "standard" treatment 
and, indeed, though less markedly, in the failures with 
chlorcyclizine. 
Altogether forty people who developed dermatitis 
had the antihistaminic treatment. An analysis of the 
position of these forty people three months after the 
end of the trial period is shown in Table V, which is 
similar to Table I and with which it should be com- 
pared. Of the nineteen people on presswork in 
Table III, six had by now been transferred by produc- 
tion and one had left for "personal" reasons, leaving 
twelve still at work when Table V was compiled. To 
these were added seven of the twelve later cases still 
at work, thus accounting for the nineteen pressworkers 




LABOUR TURNOVER OF 'TETRYL' PRESSWORKERS TREATED 
FOR DERMATITIS WITH AN ANTIHISTAMINIC 
Total entering presswork and developing dermatitis 40 
Number on presswork at end of period 19 
Number lost to presswork by end of period 21 
Reasons for loss of pressworkers:_ 
PERSONAL - discontent - 
MEDICAL - dermatitis (4), other medical 
reasons (4) 8 
PRODUCTION - moved to other jobs - 6 
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but none of these three pressmen ever developed derma- 
titis - all were "naturally immune." Thus, as far as 
treatment results in relation to production are con- 
cerned, none out of forty -nine people were successfully 
treated and working as pressmen at the end of the 
"standard" treatment period, as against nineteen out 
of forty successfully treated and working as pressmen 
three months after the end of the antihistaminic 
treatment period. Other points are evident from the 
Table and need not be detailed. 
While caution must be exercised in drawing con- 
clusions from the marked differences between these two 
seemingly comparable groups, the differences are 




additional evidence in favour of some further investi- 
gation of chlorcyclizine therapy. 
Conclusion 
Without committing ourselves to acceptance of any 
one of the several possible views concerning the 
mechanisms responsible for the skin reactions to 
"tetryl ", or to whether the seemingly beneficial 
effects of the new treatment are to be accounted for 
by the chlorcyclizine - and, if so, to its antihista- 
inic action per se or not - all the results obtained 
seem to afford strong presumptive evidence in favour 
of the chlorcyclizine as against the "standard" treat - 
nent and constitute, therefore, a strong case in favour 
of a rigorous controlled trial. 
Such a trial was accordingly designed, on the 
same lines as the large -scale M.R.C. trial of an 
antihistaminic in the common cold (Report of M.R.C. 
Committee, 1950), but with the important difference 
that the drug would be ingested in the presence of 
the medical officer and that the dose would be 
varied, up to a maximum of 350 mg per day, in 
accordance with the response of the patient. The 
trial was, in fact, started. But it came to an 
abrupt stop after only twelve people had entered it, 
for by then the labour problem had been solved - 
chiefly by the successes in the pilot trial - and as 
no further trainees were entering presswork no more 
subjects were available to us. This position has 
now been maintained for several months, thus not 
only postponing the chances of continuing the 
rigorous trial, but also, perhaps, raising the 
question of whether, on ethical grounds, its 
continuance would now be justified: It would be a 
pity, however, if it could not be continued, for, 
if the impressions already given by the pilot trial 
could be confirmed, the considerations that would 
then apply to "tetryl" dermatitis might prove to be 
of more general applicability, and might lead the 
way to a better understanding of the nature, and 
hence the possibility of control, of some other 
forms of industrial dermatitis, and even have impor- 
tant repercussions in a much wider field as well. 
-19- 
SUMMARY 
The medical and labour problems presented by 
ntetryl" dermatitis, in press workers in heavy contact 
With the substance, are indicated. 
As "tolerance" or "hardening" to the skin effects 
of "tetryl" commonly follows an attack of dermatitis, 
a solution to both problems would be afforded by a 
safe treatment that either shortened the period of 
disability from dermatitis, or enabled tolerance to be 
acquired, without the development of marked signs or 
symptoms, by men at work. 
Since the primary manifestations of skin injury 
by "tetryl" are suggestive of histamine release, it 
seemed possible that antihistaminic drugs might serve 
these purposes. But before considering a rigorous 
trial to to test this view it was necessary to see 
from preliminary or pilot observations whether such a 
trial was likely to be worth while and, if it seemed 
to be so, to get further information for use in the 
rigorous trial. 
A pilot trial with the drug chlorcyclizine hydro - 
chloride ( "Histantin" B.W. & Co.) is described. The 
results give ample justification for a rigorous trial, 
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THE MODE OF ACTION OF VASODILATOR AND VASO- 
CONSTRICTOR NERVES. By W. A. BAIN.' From the 
Department of Physiology, University of Edinburgh. (With 
five figures in the text.) 
THAT "iterative" nerves produce their effects not directly but by the 
production of chemical substances at their terminations, and the 
subsequent action of these substances on the tissue, is now fairly well 
established. Direct proof of this has been given by LoEwI (1), and 
numerous others, in the case of amphibian cardiac nerves ; by RIJLANT 
(2) for mammalian cardiac nerves ; and by FINXLEMAN (3) and by 
CANNON and BACQ (4) for the sympathetic nerves to mammalian plain 
muscle. Indirect proof that mammalian parasympathetic vasodilator 
nerves produce their effects by a similar mechanism is afforded by the 
work of DALE and GADDITM (5). 
The present paper gives a preliminary account of an attempt to 
demonstrate directly the production of specific chemical substances 
by stimulation of vasomotor nerves, the mode of demonstrating the 
existence of the substances being by their humoral transmission, from 
the site of production, to some test tissue. 
For these experiments the dog's tongue was chosen. An organ of 
considerable size, it has a parasympathetic supply to the blood -vessels 
in the lingual nerve and a sympathetic supply in the vagosympathetic 
trunk, each of which can be readily isolated for stimulation. In principle 
the experiments consisted in perfusing one side of the tongue through 
the lingual artery by means of a Dale- Schuster pump, the perfusate 
being led from the lingual vein to a bath in which was immersed a short 
length of rabbit intestine as a test tissue. 
METHOD. 
A large dog is anaesthetised with chloralose, 0.1 grm. per kilo. A 
long skin incision in the mid -ventral line, reaching from 2 or 3 cm. 
behind the symphysis of the lower jaw to 5 or 6 cm. below the larynx, 
is made. The left common carotid is cleared for as great a distance as 
possible and strong ligatures placed in position round this. A strong 
ligature is also placed, ready for securing, round the left external carotid. 
On the right side the vagosympathetic trunk is cleared for a few centi- 
metres. All the branches of the external carotid on the right side are 
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now successively identified and ligatured loosely, two ligatures being 
placed round the lingual artery. The lingual nerve is exposed and 
cleared as much as possible. Finally the right lingual vein is cleared 
and double ligatured, and a ligature placed round the anastomosing 
vein between the linguals of the two sides. 
When all is ready, the ligatures round the left external carotid and 
the branches of the right external carotid are tightly tied, the animal 
moved to the experimental table and placed in position there. The 
centremost ligature round the right lingual artery is secured, the artery 
clipped distal to this, and a cannula attached to the output tube of the 
Dale- Schuster pump is inserted and secured by the second ligature. 
The vein is now ligatured and a short glass cannula inserted. The pump 
being in action, the blood is soon washed from the tongue by the Dale 
solution used for perfusion and a clear perfusate results. This drops on 
to the outside of a specially designed glass tube down which it rapidly 
passes, and so, with the minimum possible loss of time, arrives at the 
intestine bath. This last is of the type described by SHARPEY-ScHAFER 
(6) and has a capacity of about 15 c.c. 
It should be noted that the output tube of the pump is connected 
with a mercury manometer as well as with the lingual artery. By this 
means the pressure of fluid applied to the tongue vessels can be read 
directly and can be recorded. Further, the rate of the pump can be 
altered by means of a resistance in the driving motor circuit, while the 
amount of fluid delivered by the pump can be altered instantaneously 
by means of an adjustment on the pump itself. Thus the pump can be 
made to maintain an artificial circulation in the tongue which imitates, 
in respect of pressure, flow, and frequency, the conditions which are 
maintained normally in the animal. Also, any change in the resistance 
to the flow applied through the tongue, whether brought about by 
spontaneous changes in the calibre of the blood -vessels, by changes 
imposed by stimulation of nerves, or by mechanical obstruction, will 
immediately show in the perfusion pressure record, which thus affords 
a criterion of the conditions obtaining as to the state of the blood -vessels 
at any given moment. 
That the rate of flow of fluid through the tongue was maintained 
almost unchanged by the pump even when considerable changes in 
calibre of the tongue vessels were produced by nerve stimulation, is 
shown by the record of the outflow from the tongue. This was obtained 
by allowing the perfusate, as it overflowed from the intestine bath, to 
operate a filter the movements of which are registered by electro- 
magnetic signal: each mark shows 2 c.c. 
From what has been said regarding the preparations for the experi- 
ment it is evident that the animal is intended to be alive during the 
preliminary observations : the purpose of this was to determine whether 
or not spontaneous changes in the calibre of the blood -vessels, brought 
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about by changes in the vasomotor centre itself, would produce effects 
upon the test tissue. This observation having been made, the animal was 
then usually killed by bleeding, and the lingual and vagosympathetic 
trunks prepared for stimulation. But sometimes the animal was kept 
alive during the whole experiment. 
RESULTS. 
The results are immediately divisible into two categories, negative 
and positive, the former being always associated with the presence 
of blood in the perfusate. In no case where the procedures detailed 
above had been carried out and a bloodless perfusate failed to result 
were definite effects on the test tissue obtained, either as a result of 
vasomotor- centre activity or of stimulation of vasomotor nerves. The 
negative experiments demonstrate that the positive results about to 
be described are not due simply to changes in temperature of the fluid 
with which the test tissue is in contact, consequent upon the changed 
rate of 'flow through the tongue vessels. Indeed, as is easily shown, 
such temperature changes are negligible. 
SPONTANEOUS CHANGES IN VASOMOTOR ACTIVITY 
(TRAUBE- HERING EFFECT). 
In the only case where Traube- Hering effects were exhibited co- 
incidently with 'a blood -free perfusate the result shown in. fig. 1 was 
obtained. 
The top line shows the variations in perfusion pressure consequent 
upon the changes in the calibre of the tongue vessels ; thé next line 
shows the movements of the isolated strip of rabbit intestine used as 
the test tissue ; the third line is the record of the outflow from the 
intestine bath, while the fourth and fifth lines are the signal and time 
markings respectively. 
The animal was alive and had the left common carotid tied off but 
the right internal carotid patent. 
As will be seen from the subsequent tracings, illustrating the results 
of nerve stimulation, the period between the onset of an effect in the 
tongue vessels and the appearance of the corresponding effect in the 
test tissue varies from 30 to 50 seconds. 
In the present case about 40 seconds after the commencement of 
the first rise of perfusion pressure, which rise indicates increased activity 
of the vasoconstrictor nerves, the amplitude of the intestinal contrac- 
tions has diminished very considerably. The amplitude then increases 
as the ' vasoconstriction passes off; once more diminishes as the per- 
fusion pressure rises, and so on. In other words, the contractions of 
the intestinal muscle are inhibited by an increased activity of the 
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sympathetic nerves (and /or decreased activity of the parasympathetic) 
of the blood -vessels of the tongue, and stimulated by a decrease of 
FIG. 1.- Humoral transmission of Traube- Hering effect. Top line, perfusion pressure 
recorded by Hg manometer in output of Dale- Schuster pump supplying tongue vessels ; 
second line, movements of isolated strip of rabbit intestine ; third line, output from 
tongue (recorded as overflow from intestine bath) ; fourth line, signal ; bottom line, 
time in minutes. (The above applies to all figures except fig. 4, where outflow recorder 
was not in operation.) For further description see text. 
514N41. 
frwi. 
FIG. 2.- Humoral transmission of effect of lingual nerve stimulation. Lingual nerve 
stimulated during period shown by signal. Note increased tone of intestine strip and 
increased amplitude of contractions as a result of stimulating the tongue vasodilators. 
The effect on the tone appears about 30 seconds after commencement of stimulation, 
and the effect on amplitude of the contractions about 30 seconds later still. 
sympathetic (and /or increase of parasympathetic) activity. The effects 
on the intestine having been humorally transmitted from tongue to test 
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tissue are thus presumably due to substances liberated in the tongue 
vessels by the activity of the nerves. 
STIMULATION OF LINGUAL NERVE. 
Fig. 2 is the record of an experiment in which the lingual nerve was 
stimulated. The perfusion pressure fell only slightly, and the output 




Fia. 3.- Humoral transmission of effect of lingual nerve stimulation. In this case the 
amplitude of the contractions is not much affected during the stimulation, but the tone 
of the intestine, after an initial reduction, is considerably increased. The sudden jump 
in the perfusion pressuré record is due ta a convulsive movement of the animal. 
seconds after stimulation commenced the tone of the intestine rose 
considerably, and though this fell again towards the end of the period of 
stimulation the amplitude of the contractions was greater than before. 
The average amplitude, as measured on the original tracing, was 6 mm. 
before commencement of stimulation and 10 mm. during the last 
minute of stimulation. In this case the animal was killed just before 
the commencement of the experiment. 
The next figure (fig. 3) shows the record of a similar experiment on 
the living animal, where the effect was more delayed and was preceded 
by a fall in tone of the intestine. In this case the amplitude of the 
intestinal contractions is not much affected during the stimulation, but 
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the rise in tone is considerable. Towards the end of the period of 
stimulation the animal gave a convulsive movement. The perfusion 
pressure rose momentarily, the intestinal tone fell, rose again, then 
rapidly returned to normal. The fall in perfusion pressure due to the 
vasodilatation brought about by stimulation is well marked here, and 
amounts to 20 mm. Hg. 
STIMIILATION OF VAGOSYMPATHETIC. 
In the experiment of which fig. 4 is a record, stimulation of the 
peripheral end of the vagosympathetic trunk caused an irregular rise 
FICA. 4.- Humoral transmission of effect of vagosympathetic stimulation. Note the 
diminished amplitude of the intestinal contractions as a result of stimulation of the 
tongue vasoconstrictors. In this case there is, following the stimulation, an after- 
effect of increased amplitude of contractions. This soon passes off. 
of perfusion pressure, the maximum extent of which was 30 mm. Hg. 
By 40 seconds after the commencement of stimulation the average 
amplitude of the intestinal contractions had become reduced from 12 
to 9 mm. On cessation of stimulation the movements increased in 
amplitude to an average of 16 mm. and then reverted once more to their 
original height. 
The last figure (fig. 5) is a record of a similar experiment where a. 
certain degree of vasoconstriction is maintained after cessation of the 
stimulation, and continuance of sympathetic activity is shown in the 
behaviour of the intestine. The amplitude of the intestinal contractions 
at the beginning of the record averages 35 mm. This is reduced by 
sympathetic stimulation of the tongue vessels to a minimum of 18 mm., 
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the tone of the intestine falling slightly at the same time. After cessa- 
tion of stimulation the amplitude averages 27 mm. 
While experiments along the line of those described above are being 
continued, the results here recorded afford some direct evidence in favour 
of the view that vasomotor nerves produce their effects, like the cardiac 
Fia. 5.- Humoral transmission of effect of vagosympathetic stimulation. Here the 
amplitude of the intestinal contractions is considerably diminished as a result of 
stimulation of the tongue vessels, and the tone of the muscle is slightly diminished for 
a short time. The vasoconstriction does not immediately pass off on cessation of 
stimulation -a further indication that the effect on the tongue vessels is due to 
a substance produced.by the agency of the nerves. 
nerves, by the production at their endings of specific chemical sub- 
stances : vasodilators liberating a substance with actions similar to 
acetylcholine, and vasoconstrictors a substance with actions similar to 
adrenaline. Further, the fact that in no case where blood has entered 
the perfusate in appreciable amount have definitely positive results 
been obtained, tends to support the view that the substances produced 
by nerve stimulation are rapidly destroyed by the blood : indeed it 
may be that the substances are not even passed out of the tissues into 
the blood at all under normal circumstances. 
In any case it seems unfortunate that the humoral transmissibility of 
the neuromimetic substances has ever been stressed because it has led 
a large number of physiologists to attach great physiological significance 
to this transmissibility for which there is no good evidence whatever. 
The effects of nervous stimulation are humorally transmissible under 
the conditions of experiments expressly designed to demonstrate this, 
but it is extremely doubtful if any effects so transmitted under physio- 
logical conditions are, or could be, of much significance. The main 
point about the work of LoEwi and his followers is not that the effects 
of nervous excitation are transmitted humorally but that these effects 
are due to production of chemical substances at the nerve endings. 
That the effects are humorally transmissible is the manner -indeed the 
only manner -of demonstrating directly that the nerves do act thus, 
and the very difficulty of such experiments is surely one of the main 
arguments against such transmissibility being of much, if any, physio- 
logical significance when compared with the effects produced by the 
substances at their site of production. Moreover, a mechanism exists 
which expressly tends to prevent such transmission being effective even 
if it takes place -the rapid destruction of the neuromimetic substances 
by the blood (7). 
It is thus most, probable that the substances produced by the activity 
of nerves exert their effects locally at the site of production and that 
any humoral transmission of these substances is, in normal circum- 
stances, incidental and unimportant. 
SUMMARY. 
1. Experiments on the perfused tongue of the dog, which demon- 
strate directly that vasomotor nerves produce their effects by the 
peripheral liberation of chemical substances, are described. 
2. It is shown that stimulation of the vasodilator nerves liberates a 
substance which can be transmitted humorally to an isolated strip of 
rabbit intestine and cause augmentation of the tone and /or contractions 
of this. 
3. It is shown similarly that stimulation of the sympathetic supply 
to the blood -vessels liberates a substance which diminishes the tone 
and /or contractions of an isolated strip of intestine. 
4. An experiment is described in which the effects of spontaneous 
changes in vasomotor activity (Traube- Hering effect) were humorally 
transmitted to the test tissue. 
5. The effects described are only obtained when the perfusion fluid 
(Dale's solution) is uncontaminated with blood. 
6. It is pointed out that the humoral transmission of the substances 
responsible for these effects is the method of demonstrating the 
existence of the neuromimetic substances, and that under normal 
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The mode of action of' vaso- dilator nerves, By W. A. BAIN. 
(From the Physiology Department, University of Leeds.) 
In a previous communication [Bain, 1932] it was shown that in the 
dog's perfused tongue stimulation of the chorda -lingual nerve conferred 
upon the perfusion fluid properties which rendered it excitatory to a 
piece of rabbit's isolated intestine, and it was concluded that these 
experiments gave direct support to the view that vaso- dilator nerves 
produce their effects by the production or liberation of a specific acetyl- 
choline -like substance. A similar conclusion was come to independently 
and almost simultaneously by F el d b erg, as a result of experiments on 
the tongue with its circulation intact [F e l d b erg, 1933]. 
This interpretation of our results is, however, open to the criticism 
[see e.g. Gaddum, 1935] that the acetylcholine -like substance may have 
been liberated not by the vaso- dilator fibres, as we had supposed, but 
by the secretomotor chorda fibres which are known to supply the 
numerous glands in the mucosa and submucosa of the tongue. 
Experiments have accordingly been made in which the mucous 
membrane of the tongue has been removed as completely as possible, 
thus removing at least the greater number of the glandular elements of 
the organ, with the terminations of the postganglionic fibres which 
supply them. 
The removal is most easily effected by light cauterization of the 
dorsal and lateral surfaces of the tongue, after which the mucous mem- 
brane is simply peeled off. Removal by dissection has also been tried, 
but this is both tedious and unsatisfactory. The eserinized dorsal muscle 
of the leech has been used as the test object for the transmitter of the 
chorda -lingual effects. 
Removal of the mucous membrane usually leads to the appearance 
of an acetylcholine -like substance in the perfusate, and though the 
amount so liberated gradually disappears, it is often difficult, after the 
operation, to get a blank control. Nevertheless, a comparison of the 
results of chorda -lingual stimulation before and after removal of the 
mucous membrane, makes it apparent that even if, as seems almost 
certain, part of the active substance is liberated by the secretomotor 
chorda fibres, the greater amount by far is in fact liberated by the vaso- 
dilator components of the nerve. Whatever the source of the active 
substance, liberation of which results from the operative procedures 
incidental to the removal of the mucous membrane, these procedures do 
not appear appreciably to affect the functions of the vaso- dilator fibres 
as indicated by the vaso -motor response to nerve stimulation. 
These new observations thus support our original contention that the 
vaso- dilator chorda fibres which accompany the lingual nerve transmit 
their effects- effects which are atropine resistant -by the peripheral 
liberation or production of a specific acetylcholine -like substance. 
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OBSERVATIONS ON THE INACTIVATION OF 
ADRENALINE BY BLOOD AND 
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THOUGH knowledge relating to the chemical mediation of the effects of 
cholinergic nerve activity has advanced rapidly in the course of the last 
few years, the same progress has not been made with respect to our 
knowledge of adrenergic nerve activity. It appeared to us that one of 
the factors responsible for this latter state of affairs was a lack of 
information concerning the inactivation of adrenaline under experi- 
mental conditions resembling as closely as possible the conditions which 
obtain in the body. 
The work recorded in this paper is an attempt to fill some of these 
gaps in our knowledge of adrenaline inactivation. It is necessarily 
incomplete and our interpretation of most of the phenomena described 
here for the first time must be considered tentative. Many fresh problems 
arose as the work proceeded and only a few of these have been solved: 
others we hope to deal with later. 
We have worked for the most part from first principles. Our main 
object was to determine whether adrenaline is destroyed by blood and 
other tissues in a manner analogous to that in which acetylcholine is 
destroyed, and to determine whether cocaine produces its potentiating 
action on adrenaline effects, and on effects of adrenergic nerve stimu- 
lation, by preventing or delaying this destruction, in the same way as 
eserine potentiates the action of acetylcholine. 
A chance observation, that the degree of inactivation of adrenaline 
in blood at the end of 10 hr. was no different from that at the end of 5, 
led us to investigate in more detail what happened to adrenaline when 
added to blood alone, and it is with this phase of our work that the second 
and major part of the present paper deals. The order of presentation of 
our results may seem illogical in so far as our detailed description of what 
happens to adrenaline in blood follows our description of experiments 
with liver; but it is simpler to deal with the work in the order in .which 
it was done and so, to this extent, we sacrifice logic to convenience. 
Our experience of the bio -assay of adrenaline in the earlier experiments 
enabled us to develop a method of following the inactivation over 
periods of several hours, at such intervals, and with such a degree of 
accuracy, as to make the construction of inactivation -time curves 
possible. It is in the form of such .graphs that most of our results are 
presented. Certain of our early and more or less qualitative experiments 
on the action of liver and cocaine have been repeated using this later 
technique, and the results are given in the same form as the others. Some 
of our results have been communicated to the Physiological Society 
[Bain & Suffolk, 1936; Bain et al. 1936]. 
The literature on adrenaline inactivation is scanty. For further 
information and references on the subject the reader is referred to the 
papers of Elliott [1905], Wiltshire [1931] and Blaschko et al. [1937]. 
MATERIALS AND METHODS 
General details 
In most of the experiments the medium in which we measured 
adrenaline inactivation was oxalated or defibrinated cat's blood, with or 
without added tissue slices or extracts. The blood was collected into 
clean or oxalated glass vessels from a cannula in the common carotid 
artery of a spinal or etherized cat. There was no apparent difference in 
the results with oxalated and with defibrinated blood, nor did it appear 
to matter whether the blood was obtained from spinal or from etherized 
animals. For experiments continued for 24 hr. or longer the blood was 
collected under conditions as nearly aseptic as possible, but usually no 
such precautions were taken. 
The adrenaline used was the pure synthetic levo base of British 
Drug Houses, Ltd. A concentrated stock solution of the hydrochloride 
was made by dissolving an amount of the base in a volume of N/10 HCl 
such that the solution contained 10 mg. adrenaline base per ml. From 
the concentrated stock solution we prepared, with distilled water, a 
dilute stock solution containing exactly 1 mg. of the base per ml. The 
experimental solutions in blood, in which inactivation was to be deter- 
mined, were made up by adding measured quantities of the dilute stock 
solution to measured volumes of the blood. In experiments where several 
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different initial concentrations of adrenaline in blood were investigated, 
and in which therefore the volume of blood having a given concentration 
of adrenaline was small, the dilutions were effected by making up a 
certain volume of blood to an initial concentration of, say, 100y/m1., and 
diluting measured portions of this to give the other desired and lower 
initial concentrations. 
The standard solutions of adrenaline used for the assays were prepared 
from the dilute stock solution by further dilution with distilled water. 
The concentrations of adrenaline in the standard solutions were similar 
to the initial concentrations in blood, so that quantities of standard and 
experimental solutions of the same order were being measured during 
the assays, thus, to a large extent, obviating major errors of measurement. 
For injection of very small standard quantities of adrenaline in the late 
stages of an experiment some of the standard solution was still further 
diluted before use : such diluted standards were always checked against 
the original. 
All the reactions described were carried out at a temperature of 
38 ± 1° C. except where otherwise stated. In most of the early experiments 
the experimental fluids were placed in test -tubes or hard glass flasks in 
a Wassermann bath and agitated at intervals to counteract sedimentation 
and promote full oxygenation. In all the later experiments the fluids 
were either in hard glass flasks or 25 ml. Jena glass vaccine bottles and 
were agitated continuously during the whole experiment. 
Method of assay 
The " adrenaline values " or " adrenaline equivalents " of the various 
experimental fluids were determined by blood pressure assay on cats, by 
what may be called the method of "continuous assay ". In the earliest 
experiments we used both spinal and anaesthetized cats, but as the former 
proved much more sensitive to adrenaline all our later assays were made 
on spinal animals : all the results reported here refer to experiments on 
atropinized spinal preparations which had been "rested" for 2 -3 hr. 
after transection of the spinal cord and destruction of the brain. 
The arterial blood pressure was recorded from the left common 
carotid artery, and the anticoagulant fluid in the manometer system was 
a half -saturated solution of sodium bicarbonate. Injections were made 
into the right external jugular vein through a narrow metal cannula the 
proximal end of which fitted the nose of a record syringe : the cannula was 
provided with a stilette. 
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All the injections of experimental or standard solutions were made 
up to 1 ml. by dilution with Locke solution 'immediately before injection 
and were washed in with a further 0.5 or 1 ml. of Locke solution, makin g 
the volume of fluid injected at each observation 1.5 or 2 ml. according 
to the particular experiment. Control experimental fluids were treated 
in an exactly similar way. In some instances, where the amount of 
adrenaline left in the experimental fluids was small, or where the initial 
concentration was itself small, as much as 3 ml. of undiluted blood and 
adrenaline, or of control blood, had to be injected at an observation; but 
in general the total amount of undiluted experimental fluid measured 
out and subsequently diluted before injection was not more than 0.5 ml. 
and, in the early stages of an experiment, was usually less than 0.1 ml. 
These small amounts were measured into little conical glass dishes, and, 
a few seconds before the injection was due, were made up to volume 
with Locke solution from the injection syringe, rapidly mixed by 
barbotage, taken up and injected. 
Injections were given at regular intervals of 3 -6 min., the interval 
in any particular experiment depending chiefly on the time taken for the 
blood pressure to recover from a previous injection. After giving a 
number of injections of various doses of standard adrenaline, in order to 
determine the initial sensitivity of the animal, we continued with the 
injections of the standard doses within the range of greatest sensitivity. 
At convenient intervals a standard injection was replaced by an experi- 
mental one, the volume of experimental fluid taken up for dilution and 
injection being such as was calculated to bring the blood pressure rise 
between two of the standard rises, and as near to one of these as possible. 
Injections of standard and experimental fluids were continued in this 
way until the end of the experiment. 
An important point about this continuous assay technique is that 
after 20 or 30 injections a large rise of blood pressure may be got with an 
amount of adrenaline which, at the beginning of the experiment, gave 
a small rise or no rise at all. This increase in sensitivity to adrenaline is 
always seen under the conditions of our experiments and usually occurs 
without any appreciable change in the resting blood pressure level. 
Sometimes the maximum increase may be only 80 p.c. for a given dose 
or it may be as much as 800 p.c. Whatever the extent of the increase it 
usually takes place smoothly, provided the injections are continued at 
regular intervals and that the heights of the blood pressure rises in 
response to the injections do not suddenly become much greater or much 
smaller, on the average, by marked alterations in the amounts of 
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adrenaline injected. The sensitivity generally reaches a maximum after 
40 or 50 injections, may stay at this level for hours, and then decrease 
either gradually or suddenly. This decrease usually heralds the death of 
the animal, though in some instances there may be a fall after a few 
hours and the sensitivity persist at this lower level for a further period. 
The rate at which maximum sensitivity is attained seems to depend not 
so much on the number of injections given as on the blood pressure rises 
which they cause : the larger the individual rises of blood pressure the 
quicker is the rise of adrenaline sensitivity. 
The importance of this change of sensitivity need not be stressed but 
it shows the absolute necessity for continued injections of standard 
adrenaline solutions throughout an experiment. It is also evident that 
if a high degree of sensitivity in the animal is desired before the assays 
proper are started, this can be achieved by giving a sufficient number of 
standard injections beforehand. For the type of work described here the 
increase of sensitivity is advantageous in that as the adrenaline disappears 
from our experimental solutions we are not compelled to increase the 
amount of such solutions injected to the same extent as would otherwise 
be necessary. 
The standards to be injected are determined in the first place by the 
initial sensitivity of the animal and usually have to be modified later on: 
thus at the start of an experiment convenient standards may be 3, 3.5 
and 4y or more and, when full sensitivity is established, 0.5, 1 and 1.5y 
or less. 
Our method of arriving at the actual amount of adrenaline in the 
different volumes of experimental fluid injected is as follows: The blood 
pressure rises are measured and plotted on graph paper against time as 
abscissa. A line is drawn through each set of points representing rises for 
a particular dose of standard. The adrenaline value of any given experi- 
mental injection is then determined by observation or calculation. 
As noted above, standards were not usually closer than 0.5y, but in 
good experiments, where the sensitivity is high and the sensitivity curves 
are smooth, the adrenaline equivalent of the actual volume of fluid 
injected can be estimated to 0.ly, especially if the position of inter- 
mediate points on the sensitivity curves is determined on the basis of 
a few injections and interpolated accordingly. In experiments where 
low concentrations of adrenaline had to be determined, standards 
differing by as little as 0.05y were used. 
A remarkable feature of these assay experiments is the large number 
of injections that can be given to a single spinal animal without causing 
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any appreciable change in the level of the resting arterial blood pressure, 
or in the accuracy of the adrenaline determinations. Most of our cats 
have had at least 60 injections and many well over 100, and it is very 
seldom that an experiment has had to be abandoned because of irregular 
responses at a late stage in the assaying. Bad cats are usually so from 
the start. 
RESULTS 
Part I. Preliminary observations on inactivation by blood and tissues 
In oxalated blood plasma and in blood serum at body temperature 
the inactivation of adrenaline proceeds to completion as it does in normal 
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Fig. 1. To show rate and extent of inactivation of adrenaline at body temperature in 
(i) oxalated or defibrinated whole blood, (ii) blood plasma, and (iii) blood serum. 
Initial concentration of adrenaline 40y /ml. in all cases. Data from Exps. A 47, 50, 
58, 63 and 64. 
linear manner during the greater part of its course and then tails off; 
it is more rapid in serum than in plasma. In oxalated or defibrinated 
blood inactivation of adrenaline does not proceed to completion: it 
proceeds in an exponential manner and ceases when an amount, which 
depends on the initial concentration of adrenaline, has disappeared. 
These facts are illustrated in Fig. 1, which shows the combined results 
from five typical experiments. 
The difference between the behaviour of adrenaline in plasma and 
in serum seems to be chiefly one of rate. It is not accounted for by the 
absence of oxalate from. the serum -since oxalated serum behaves in 
exactly the same way as normal serum -and it may be due simply to the 
difference in protein content of the two fluids. Comparison of the be- 
haviour of adrenaline in whole shed blood, and in plasma or serum, shows 
that the difference here is of another order : it is a difference in kind. 
In shed blood, whether oxalated or defibrinated, it seems that inactivation 
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proceeds to what it is convenient to term an " equilibrium concentration" 
of adrenaline beyond which no further inactivation can be demonstrated. 
It thus appears at the outset, from the marked contrast between the 
action of whole blood on adrenaline and its action on acetylcholine, that 
the hypothetical " oxidase" for adrenaline, corresponding to the known 
esterase for acetylcholine, either does not exist in the blood or, if it does, 
is incapable of exerting its full action under the conditions of our 
experiments. That we still get this equilibrium concentration even with 
full oxygenation of the blood and adrenaline shows that, apart altogether 
from the question of oxidizing enzymes, and apart, too, from the question 
of what has happened to the inactivated portion of the original adrenaline, 
full auto -oxidation itself is in some way prevented in whole blood. 
Having failed to show complete inactivation of adrenaline by blood, 
we turned our attention to the possible effects of tissues added to blood 
and adrenaline in vitro. 
Effects of tissues on adrenaline activation in blood. The tissues were 
removed from the animal used to supply blood for the experiment, cut 
into thin slices with a razor, rapidly washed to free them from blood and 
the excess moisture removed by filter papers, weighed, and added to the 
blood in the proportion of 1 g. of tissue /ml. blood. Adrenaline was then 
added to the mixture and to the control blood to give the same initial 
concentration per ml. of blood in each. Often the reverse procedure was 
adopted, i.e. 1 ml. of blood and adrenaline per g. tissue, mixed im- 
mediately beforehand, was added to the weighed liver slices. Control 
mixtures of tissue and blood were also set up and the different mixtures 
incubated in the usual way. 
Of the tissues studied liver showed by far the greatest activity, and 
so attention was concentrated on it. Of the others, skeletal muscle was 
slightly active and kidney tissue intermediate between skeletal muscle 
and liver. Experiments on lung tissue proved fruitless because of the 
large amounts of an atropine -resistant histamine -like substance liberated 
during incubation. 
That addition of liver slices to blood and adrenaline leads to the 
complete disappearance of adrenaline activity from the blood is shown 
in Fig. 2. This activity of liver is diminished by dipping the tissue in 
boiling water, and abolished by boiling for 2 min. 
The activity of liver appears to be diminished by acid. This statement 
is based on two experiments (A 16 and 17) in which the activity of liver 
was so little in evidence as to lead us to suspect some error. It was found 
that the acid used in making up the stock adrenaline was N instead of 
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N /10. The activity of liver does not seem to be dependent on a simple 
catalysis of auto -oxidation, consequent upon contact of the tissues with 
metal in the course of their preparation. Even a bright copper strip or 
copper filings added to blood and adrenaline, or to blood, liver and 
adrenaline, does not affect appreciably the disappearance of adrenaline 
activity under conditions where neither the blood nor the liver has 
hitherto come into contact with metal. This is in direct contrast to what 
happens when metallic copper is added to a solution of adrenaline in 
Ringer's fluid, as first pointed out by Schild [1933]. The fact that the 
inactivating power of liver is abolished by boiling is also against the 
view that such an effect could be responsible. 
Adrenaline in blood 
O in blood +couine 
in blood +liver 
O in blood +liver +cocaine 
0 I 2 3 4 5 6 7 
Time in hours 
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Fig. 2. Fig. 3. 
Fig. 2. To show contrast between inactivation of adrenaline in oxalated or defibrinated 
blood with and without addition of liver slices. Upper curve shows inactivation in 
blood alone: lower curve inactivation in blood to which liver (1 g. /ml.) has been added. 
Initial concentration of adrenaline 20y /ml. Data from Exps. A 30-34, 36, 37, 41-43, 
51, 52, 56, 62, 67 and 68. 
Fig. 3. To show that cocaine does not inhibit the inactivation of adrenaline in blood or in 
blood to which liver has been added. Initial concentration of adrenaline 20y /ml. and 
of cocaine 10y/ml. Data from Exps. A 61 and 62. 
Liver ground with sand is active; but, when ground with sand in 
saline or Locke, filtrates from such concoctions, as free as possible from 
cells and from cell fragments, have proved inactive in our hands. 
Similarly, cell free extracts with N /100 HC1, with 25 p.c. glycerol and 
with acetone were inactive. Our results with extracts were thus dis- 
appointing [cf. Schütz, 1933; Blaschko et al. 1937] and we could only 
be sure of results when we used liver slices or the unfiltered concoctions 
got by grinding the material with sand. We preferred the slices. 
Attempts to abolish the activity of liver by means other than heating 
were not satisfactory. We could diminish the activity considerably by 
withholding oxygen but we never succeeded in abolishing it completely 
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even by bubbling N2 through the blood. Addition of KCN had no effect 
in the doses which we investigated (10- 20y /ml.) and formol, which we also 
tried, proved useless because of its own inactivating effect on adrenaline 
[Cr a m er, 1911], an effect quite evident with as little as 5y /ml. 
Effect of cocaine on adrenaline inactivation. Though the point was 
perhaps not yet proven, liver appeared to produce an effect on adrenaline 
which might provisionally, at least, be attributed to an enzyme (oxidase) 
and the last part of our first object, as explained in the introduction, 
was to determine whether cocaine had an inhibitory effect on this action 
and on the action of blood itself so far as this went. (For a review of the 
early literature relating to the action of cocaine on the effects of adrenaline 
and of sympathetic nerve stimulation see Tr e n d e l e n b u r g [1924]. ) 
In making up the experimental solutions cocaine hydrochloride was 
first added to a portion of the blood; liver slices were then added to a 
portion of the blood and cocaine, and to a portion of control blood; the 
adrenaline was added to control and to experimental fluids last of all. 
In some experiments the liver was added last of all. The particular 
procedure used made no difference to the results. The concentrations of 
cocaine used were from 5 to 20y /ml., i.e. a total per ml. many times 
greater than that sufficient to produce a demonstrable effect on adrenaline 
sensitivity when injected intravenously into a cat. 
In determining the adrenaline values of blood, etc., in which cocaine 
was present, it was found convenient to inure the test animal to the 
effects upon adrenaline sensitivity of further additions of cocaine by 
administering from 1 to 10 mg. of cocaine hydrochloride subcutaneously 
before the experiment started. Failure to do this resulted in highly 
inconsistent results due to the fleeting and /or step -like changes in 
adrenaline sensitivity induced by the minute amounts of cocaine in the 
experimental injections. 
Fig. 3 illustrates the results of two such experiments. Cocaine, added 
to blood or to blood and liver, has no inhibiting effect on the inactivation 
of adrenaline under the conditions of our experiments, and thus, pre- 
sumably, does not produce its well -known potentiating action on the 
effects of adrenaline, and on certain actions mediated by sympathetic 
nerves, by inhibiting adrenaline inactivation. 
From the experiments so far described we see that the hypothetical 
analogy between the mechanisms responsible for the inactivation of 
adrenaline and of acetylcholine breaks down in one important respect, 
for while whole blood is extremely active in destroying acetylcholine this 
is not so with adrenaline. The hypothetical analogy between the actions 
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of eserine and cocaine, in so far as these substances affect the actions of 
acetylcholine and adrenaline and the actions of autonomic nerves, breaks 
down completely. Thus while eserine inactivates choline- esterase, cocaine 
fails to inactivate the inactivating principle (or principles) of tissues and 
so must produce its potentiating or "sensitizing" action to adrenaline 
and to adrenergic nerve stimulation in some other way. 
Part II. Further observations on adrenaline inactivation in blood 
That an "equilibrium ", with respect to inactivation, is reached in 
blood was confirmed by many experiments. For any given initial con- 
centration the equilibrium concentration varies somewhat from blood 
bo. 
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Fig. 4. To show variations of equilibrium value in different experiments with the same 
initial concentration of adrenaline (40y /ml.). Data from Expo. A 47, 49, 51, 52, 53, 
55, 57, 58, 63, 64, 67, 74 and 85. 
to blood. This fact is evident from Fig. 4, which gives the graphed results 
of a number of experiments in which the initial concentration of adrenaline 
was 40y /ml. In any individual experiment the equilibrium concentration 
is quite definitely established. The average value of the equilibrium 
concentrations for an initial concentration of 40y /ml. was 17.8y (13 
experiments) and the individual values ranged from 14y to 24y /ml. 
(see Fig. 5a). 
It is obvious that these individual variations may partly be due to 
errors and thus bé insignificant; for if the initial concentration is more 
than that estimated by, say, 2y /ml. and the standard solution used for 
assay less by 2y /ml. than estimated, the assay (assuming there are no 
inherent errors in this) will give an equilibrium value 4y /ml. higher than 
the actual; but the greatest care in measuring the blood and the adrenaline 
solutions has not diminished the variation, and we therefore consider it 
to be probably significant. As we shall see later, it may be related to 
differences in the corpuscle : plasma ratio in different samples of blood. 
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In addition to these individual variations for a given initial concen- 
tration there is a variation in the equilibrium concentration related to 
differences in the initial concentration of adrenaline. This relationship 
for different initial concentrations from 60y downwards is shown in 
Fig. 5 a. The points through which the graph is drawn represent the 
average values for that number of observations indicated for each initial 
concentration by the bracketed numerals on the right -hand side of the 
chart; while the small vertical lines, lateral to the main points, represent 
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Figs. 5a and 5b. To show variation in equilibrium value of blood and adrenaline with 
different initial concentrations. Fig. 5a shows the variation for initial concentrations 
from 60y /ml. downwards. For description see text. Fig. 5b shows in greater detail 
the variations of the equilibrium value for initial concentrations from 10y /ml. to 
0.5y /ml. Each point for a particular initial concentration on this chart represents a 
separate experiment. Data for Fig. 5b from Exps. A 8, 44, 64, 65, 66, 89 and 92. 
a physiological point of view the most interesting part of this curve is 
that which relates to initial concentrations between, say, 10 and 0.5y, 
and so that part of the curve is reproduced in greater detail as Fig. 5 b. 
Unfortunately, however, it is with these small initial concentrations that 
our method tends to break down, for the simple reason that accurate 
estimates of the adrenaline activity at equilibrium involve the injection 
of relatively enormous quantities of blood (2 -3 ml.). Nevertheless, the 
results, carefully controlled, are concordant so far as they go. But the 
experiments will have to be repeated using other techniques before we 
could feel justified in laying much stress on them. In the meantime 
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we can confine our attention to the results got with the relatively 
unphysiological initial concentrations of 20- 40y /ml. without prejudice 
as to what happens with very small initial concentrations. 
The part played by the corpuscles in the inactivation of adrenaline by 
blood. The fact that adrenaline becomes completely inactivated in plasma 
and in serum but only partially in oxalated or defibrinated blood led 
us to consider the possible significance of the corpuscles in the phenomena 
exhibited by blood. We therefore made experiments in which oxalated 
blood, with added adrenaline, was allowed to come to equilibrium, the 
corpuscles then being spun off and the adrenaline value of the plasma 
determined as soon as possible after separation and at intervals thereafter. 
We soon saw that the adrenaline value of the plasma under these circum- 
stances diminishes in the same way as it does when adrenaline is added 
to plasma in the first place. Thus, whatever the property of the 
corpuscles which prevents complete disappearance of adrenaline from 
blood, the corpuscles do not confer on the plasma any "protective" 
action which persists after they have been removed. 
Extrapolation of the equilibrium plasma inactivation curve, after 
separation of the cells, indicates that at the time of separation of the 
corpuscles the adrenaline value of the plasma represents the whole 
adrenaline activity of the equilibrium mixture. Exp. A 57 may be given 
as an example : A sample of blood and adrenaline, 40y /ml., came to 
equilibrium at 15y /ml. Separation of cells from the plasma from 40 ml. 
of this equilibrium mixture gave 18 ml. of cells and 22 ml. of plasma. 
The adrenaline value of the plasma 30 min. after separation was 25y /ml. 
and 2 hr. 50 rain. after separation 18y /ml. (average values for triplicate 
readings at 5 min. intervals). Extrapolation from these points, which lie 
in the linear part of the plasma inactivation time curve, gives the plasma 
adrenaline concentration at the time of separation as 26.5y/ml. Now, if all 
the adrenaline of the equilibrium mixture (i.e. 15y/ml.) is in fact present in 
the plasma, the adrenaline content of the separated plasma at the time 
of separation should be (15/1 x 40/22)y/ml., i.e. 27y /ml. approximately, 
which is not significantly different from that found. Direct determination 
of the plasma or serum adrenaline immediately after separation confirms 
this type of result, and so we have the further important fact that all the 
adrenaline activity of an equilibrium mixture, as determined by bio -assay 
of the intact mixture, resides in the plasma or serum of the mixture. 
It immediately appears, therefore, that the blood corpuscles play an 
essential part both in the establishment and in the maintenance of the 
equilibrium phenomena which we have described. 
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Adrenaline associated with the cells of an equilibrium mixture. Having 
shown that serum or plasma, freshly separated from an equilibrium 
mixture, appeared to contain an amount of adrenaline which accounted 
for the whole activity of the equilibrium mixture, it remained to confirm 
this by showing that the corpuscles from an equilibrium mixture showed 
by themselves no adrenaline activity. This was done. Whole corpuscles 
from an equilibrium mixture show no adrenaline activity when taken up 
in Locke solution and immediately injected into the test animal. If, 
however, the cells are left in Locke solution, or in fresh plasma or serum, 
the mixture soon acquires an adrenaline activity which gradually increases 
to a constant value, a fact which immediately suggests the survival of 
some of the missing adrenaline in reversible association with the cor- 
puscles. This is dramatically demonstrated when corpuscles separated 
from an equilibrium mixture are laked either by the action of acid or by 
freezing: they then exhibit a marked adrenaline activity not shown by 
control laked corpuscles. From such observations it became apparent 
that the adrenaline equivalent of an equilibrium mixture, i.e. the 
equilibrium concentration, does not in fact represent the total amount 
of adrenaline in such a mixture, but that a further amount is present in 
or on the corpuscles, an amount incapable under ordinary circumstances 
of exhibiting its presence by an action on the test animal. 
The next step was to determine the amount of adrenaline associated 
with the corpuscles of an equilibrium mixture. Two methods of doing 
this were open to us : One was to separate the cells from the mixture, 
determine the relative cell/plasma or cell /serum volumes, lake the cells 
and find their adrenaline value per unit volume; the other was to lake 
the equilibrium mixture with dilute hydrochloric acid and find the 
adrenaline value of the laked mixture.. Both methods were used and some 
results are summarized in Tables I a and I b. 
TABLE Ia. Recovery of adrenaline from equilibrium mixtures. Plasma adrenaline, from 
separated equilibrium plasma, is calculated as adrenaline equivalent per ml. original 
whole blood. Corpuscle adrenaline, from separated equilibrium cells, is calculated as 
adrenaline equivalent per ml. original whole blood 
Adrenaline Adrenaline Total adrenaline 
Initial value plasma value cells Adrenaline value recovered 
cone. (y /ml. whole (y /ml. whole cells +plasma (p.c. of initial 
(y /ml.) blood) blood) (y /ml.) adrenaline) 
20 9.4 5.9 15.3 76.5 
40 14.8 14 28.8 72 
40 15.8 12.4 28.2 70.5 
60 26.2 19.1 45.3 75 
Average 73.5 
TABLE Ib. Recovery of adrenaline from equilibrium mixtures. Corpuscle 







Adrenaline equivalent Total adrenaline 
laked equilibrium laked equilibrium 
mixture mixture 
(y /ml.) (p.c. original) 
20 6.7 17.0 85 
20 7.7 14.5 72 
40 13.3 30.9. 77 
40 15.5 33.5 84 
60 29.0 43.3 72 
60 26.0 52.0 87 
Average 79.5 
It will be seen that a somewhat greater "recovery" of adrenaline was 
got by Taking the equilibrium mixture than by separating the cells from 
the serum or plasma. This difference may be accounted for by loss of 
cell -adrenaline in the experimental procedures necessary with the 
separation method. The average "recovery" or "total equilibrium" 
adrenaline from 10 equilibrium mixtures selected at random (initial 
concentration 40 and 20y /ml.) represents approximately 80 p.c. of the 
original amount added. Thus while an average of 56 p.c. of the initial 
adrenaline (40 or 20y /ml.) becomes physiologically inactivated by the 
time equilibrium is reached, all of this amount is not destroyed; a further 
36 p.c. of the original amount can be recovered from the corpuscles in 
which situation it is ordinarily incapable of manifesting a pressor action 
on the test animal. We conclude therefore that the total irrecoverable 
adrenaline of an equilibrium mixture is actually only about 20 p.c. of 
the original, as against the apparent 56 p.c. of the original as given by 
the equilibrium adrenaline value. 
If the procedure for obtaining an inactivation curve for blood 
and adrenaline is followed out and alternate samples of blood are 
laked immediately before assay two separate curves result, the normal 
( "apparent ") inactivation curve, and what one might call for con- 
venience the "virtual" inactivation curve. The uppermost graph in 
Fig. 6, constructed from the data of two experiments (A 63 and 64),. is 
an example of such a "virtual" inactivation curve. It would seem from 
such results that the "irrecoverable" adrenaline is lost before equilibrium 
is reached, since the assay curve for the laked samples becomes horizontal 
before the normal inactivation curve does so. 
Whether the irrecoverable adrenaline of an equilibrium mixture is 
destroyed by oxidation or otherwise, or is inactivated in the same way 
as the recoverable cell adrenaline but in a less easily reversible manner, 
or is inactivated by combination with some constituent of the blood, 
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irreversibly or otherwise, we are not at present in a position to say. Nor 
are we able to say whether the adrenaline recovered by laking an 
equilibrium mixture, or separated equilibrium corpuscles, is inactive 
because it is inside the corpuscles in a free state, or is adsorbed on the 
corpuscles, or both. Whatever be the truth it is certain that, so far as 
the recoverable adrenaline associated with the corpuscles is concerned, 
the mechanisms involved can be partially reversed under circumstances 
not involving destruction of the corpuscles. If, for example, cells from 
an equilibrium mixture are added to fresh serum or plasma this mixture 
acquires and shows a progressively increasing adrenaline value which 
ultimately becomes constant -that is, comes to equilibrium : the 
adrenaline value of the separated cells diminishes accordingly. Similarly, 
if fresh blood is added to an equilibrium mixture the equilibrium changes 
and in 3 -5 hr. has a value near to that which it would have had if the 
initial adrenaline had been added to the final volume of blood in the first 
place, and the adrenaline value of the cells is diminished in consequence. 
What is perhaps a more important point, and one which may be 
considered as giving evidence that the recoverable adrenaline associated 
with the cells is normally inactive simply because it is within them, or 
is adsorbed by them, and that the irrecoverable adrenaline may be lost 
in another way, is the fact that the integrity of the corpuscles does not 
appear to be necessary either for the loss of the irrecoverable adrenaline 
or for the persistence of that amount normally associated with the cells 
and normally recoverable after laking either the equilibrium mixture or 
the separated equilibrium cells. This is illustrated by the following 
experiment (A 85) : 
Oxalated blood, collected aseptically, was divided into two portions. 
One of these was laked. 
In this experiment, and also in most of those in which we studied inactivation of low 
initial concentrations, the blood was laked by freezing with liquid air. 10 ml. or so of blood 
at a time were placed in a hard glass test -tube the bottom of which was dipped in liquid 
air until the blood froze solid. It was then rapidly thawed by running warm water over 
the outside of the tube. Often the whole process was repeated to ensure thorough laking. 
Samples of each portion having been retained as controls adrenaline 
was added to each of the remaining portions to give an initial concen- 
tration of 40y /ml. Experimental and control samples were then incubated 
with continuous mechanical agitation in stoppered sterile vessels. 
Immediate assay gave initial values of 39 and 41y /ml. for the normal and 
the laked portions respectively. 24 hr. later the adrenaline value of the 
normal sample was 16.7y /ml. and of the laked sample 29y /ml. A portion 
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of the normal 24 hr. sample laked with liquid air had an adrenaline 
equivalent of 30y /ml. The 24 hr. equilibrium value is thus well within 
the normal limits, as is the total recoverable adrenaline from this equili- 
brium mixture. The adrenaline value of the sample laked before the 
adrenaline was added to it 24 hr. previously is, however, not significantly 
different from the adrenaline value of the laked equilibrium mixture. It 
thus appears (1) that the irrecoverable adrenaline does not depend for its 
loss upon the integrity of the corpuscles, and (2) that the total recoverable 
adrenaline is the same whether the corpuscles are intact or not, that is, 
whether part of it is in a state in which it is incapable of exercising an 
effect on the test animal by reason of association with intact corpuscles, 
or is free in the plasma along with destroyed corpuscles, in which 
situation it is free to exercise its action on the test animal from the 
beginning. 
Relative amounts of adrenaline associated with cells and with plasma or 
serum of equilibrium mixtures. A further interesting point relating to the 
corpuscle adrenaline is that at equilibrium the adrenaline equivalent of 
the corpuscles to greater, volume than that of 
the plasma.. If, for example, making use of the 4 : 6 corpuscle /plasma 
ratio determined by the hwmatocrite and the equilibrium and laked 
equilibrium values given in Table I b, we calculate the corpuscle adrenaline 
and plasma adrenaline concentrations respectively for each of the six 
blood samples of that table, we find the average values for each of the 
three sets of initial concentrations to be 21.4 and 12y /ml. for the original 
20y /ml. samples, 44.5 and 24y /ml. for the original 40y /ml. samples, and 
50.4 and 45.8y/ml. for the original 60y /ml. samples. 
If we calculate the plasma and corpuscle adrenaline concentrations 
from the average equilibrium values for different initial concentrations 
(see Fig. 5a), assuming an 80 p.c. recovery and a 4 : 6 corpuscle /plasma 
ratio, the differences are not so striking as those just quoted; for an initial 
concentration of 10y /ml. they are for corpuscles and plasma, in that order, 
10.25 and 6.5y /ml. ; for 20y, 18 and 14.7y /ml. ; for 40y, 35.7 and 29.5y/ml. ; 
and for 60y, 56.2 and 42.5y/ml. respectively. The differences are, of 
course, reduced still further if the total recovery is reduced or the 
corpuscle /plasma ratio approaches nearer to unity. But that the corpuscle 
adrenaline concentration at equilibrium probably is significantly greater 
than the plasma adrenaline is confirmed by experiments in which the 
total recovery was accurately estimated and the corpuscle /plasma ratio 
determined at the outset by the addition of known volumes of spun cells 
to known and widely different volumes of separated plasma. In the 
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experiment which we quote, spun cells from oxalated blood were added 
to separated plasma in four different ratios; adrenaline was added to 
give an initial concentration of 20y /ml. of the mixtures, and allowed to 
come to equilibrium. In addition to the equilibrium values, the total 
adrenaline recovery was determined in each instance; from these figures, 
together with the known corpuscle /plasma ratios, the plasma and corpuscle 
adrenaline concentrations were calculated. These results are set forth in 
Table II. (It must be clearly understood, however, that in speaking of 
TABLE II. Equilibrium values, total recovery, and corpuscle and plasma adrenaline values 
in blood with altered corpuscle /plasma ratios. Initial concentration of adrenaline 
20y /ml. in all cases. Cell (or plasma) conc. = c [or p] amount x 
total volume 
( c [or p] vol. ) 
Adrenaline 
equivalent 
laked equi- Total 
Equilibrium librium mixture adrenaline Plasma Cell 
value (i.e. plasma recovered adrenaline adrenaline 
(i.e. plasma and cell (p.c. cone. cone. 
Ratio adrenaline) adrenaline) initial (y /ml. (y /ml. 
cells: plasma (y /ml.) (y /ml.) cone.) plasma) cells) 
2 3.9 15.3 76.5 11.7 17 -1 
4 : 6 7.5 14.3 72.0 12.5 17.0 
(normal) 
4 : 10 9.7 16.0 80.0 13.6 22.0 
4 : 16 11.0 16.7 84.0 13.7 28.5 
the " cell concentration" of adrenaline we do not infer that the adrenaline 
is in fact in simple solution within the cells at equilibrium: adsorption 
may well be the main, or indeed the exclusive factor at work. At the 
present time we cannot commit ourselves either one way or the other.) 
In an earlier part of this paper it was pointed out that the individual 
variations in the equilibrium concentrations for different initial con- 
centrations of adrenaline might be partly accounted for by differences in 
the corpuscle /plasma or corpuscle /serum ratios in the different samples 
of blood. The effects upon the equilibrium value of alterations in the 
corpuscle /plasma ratio, as in the experiment just quoted, show that this 
view is perhaps justified. 
Experiments with low initial concentrations of adrenaline. We have 
hitherto dealt for the most part with results arrived at in the study of 
initial concentrations of 20 and 40y of adrenaline per ml.; we revert 
finally to the question of much lower initial concentrations. We have 
already alluded to these (p. 243), and to the difficulties of investigating 
them by our method. The chief difficulty arises from the relatively 
enormous quantities of blood that have to be injected in the later stages 
of such experiments in order to get an estimate of the adrenaline present, 
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The numbeí of injections is thus limited and the difficulties both of 
making an assay and of making adequate controls are further increased 
by this restriction. More serious, however, than the difficulties introduced 
by the simple volume factor is the fact that the controls often cause an 
atropine -resistant depressor effect which is greatly exaggerated when the 
blood is laked. Sometimes these presumably histamine effects are absent 
even with 5 ml. injections of blood: there is considerable variation either 
in the content of the depressor substance in different samples of blood 
and /or in the sensitivity of the test animals to it. In view of these 
difficulties, however, we regard our results with these low initial con- 
centrations with caution until such time as the experiments can be 
repeated using other techniques. 
Keeping this proviso in mind we present in Table III the results of an 
experiment (A 92) conducted under the best conditions, i.e. where the 
TABLE M. To show equilibrium values, total recovery and relative corpuscle and plasma 
adrenaline concentrations with low initial concentrations. Figures in brackets are the 








mixture Cell cone. Plasma cone. 
(y /ml.) (y /ml. cells) (y /ml. plasma) 
5.0 1.8 (36) 3.7 (74) 4.75 3.0 
2.0 0.45 (22.5) 1.24 (62) 1.97 0.75 
1.5 0.25 (16.6) 0.70 (50) 1.12 0.42 
1.0 0.075 (7.5) 0.25 (25) 0.44 0.12 
0.5 0.025 (5) 0.10 (20) 0.19 0.04 
sensitivity of the test animal to adrenaline was extraordinarily high and 
the controls had no apparent histamine activity. The chief points of 
interest appear to be: (1) that as the initial concentration of adrenaline 
is lowered from 5 to 0.5y /ml. the percentage of the original adrenaline 
represented by the equilibrium value falls from 36 to 5, and the total 
recovery from 74 to 20 ; (2) at equilibrium the " cell concentration ", 
expressed as a multiple of the plasma concentration, rises from about 1.6 
for an initial concentration of 5y /ml. to about 4.7 at 0.5y and this despite 
the fact that if histamine is interfering with the assays it would tend to 
diminish the observed cell concentration of adrenaline to a greater extent 
than the plasma concentration. If adsorption is the main factor at work 
in determining the phenomena which we have described in blood it may 
be that the comparatively low equilibrium values with the very small 
initial concentrations are due to more complete adsorption, and the low 




Detailed discussion of the results reported in this paper would be 
premature at this stage and must wait until some further facts are 
forthcoming. One or two observations of a general nature may, however, 
be permissible now. In the first place, we would point out the advantage 
of using blood as a medium in experiments on adrenaline inactivation. 
Despite the fact that Oliver & Schäfer in 1895 pointed out the feeble 
adrenaline inactivating power of blood, most studies of adrenaline 
inactivation since that time have been carried out using Ringer fluids 
as the medium. The rapidity of free oxidation in this medium, taken 
together with the rapid inactivation of adrenaline in vivo, appears to 
have led many, at least implicitly, to identify the processes in Ringer's 
fluid and in vivo, or if not going so far, at least to regard the process in 
Ringer's fluid as the standard against which inactivation by tissues or 
other factors is to be measured. This is seen, for example, in Miss 
Wiltshire's [1931] work. By taking blood as a medium and the 
inactivation of adrenaline in blood as a physiological standard the 
fallacious arguments and the contradictory interpretations which arise 
when other media are used would to a large extent be obviated. 
The only general conclusion which we can safely draw from the work 
recorded here is that blood itself is probably but of small significance in 
determining the inactivation of adrenaline in the body and that it is in 
the tissues almost exclusively that the conditions for this inactivation 
are fulfilled. It is true that under the conditions of our experiments 
complete inactivation of 40y adrenaline by 1 g. of liver -the most active 
of all the tissues we examined -takes some 4-5 hr. But this length of 
time does not in our view make it unlikely, as B ac q [1936] rather seems 
to suggest, that the same mechanism is in fact the one responsible for 
the rapid inactivation of adrenaline in vivo. In the first place, the 
conditions under which our experiments are carried out are manifestly 
much less favourable to the inactivating property of the tissues than are 
the conditions in vivo. In the second place, even if 1 g. of liver does take 
4 hr. to inactivate 40y of adrenaline, surely it is not too much to expect 
the 80 g. or so of cat liver in vivo, taken together with the lesser but very 
significant inactivating effect of many if not most of the other tissues of 
the body, to inactivate the same amount in a few minutes. Apart from 
such considerations, however, an examination of the inactivation -time 
curves for the different media we have investigated will immediately 
show how different are the inactivation rates in these media. Thus the 
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approximate times for 25 p.c. inactivation are in blood plasma 180 min., 
in serum 80 min., in blood 40 min., and in blood +liver 6 min. These 
facts are illustrated in Fig. 6 which summarizes most of our results. The 
relatively high initial rate of inactivation by liver is obvious from the 
graph, and the tailing -off may well be due partly to accumulation of 
oxidation products, a factor which might not operate to anything like 
.a Ioo 
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Fig. 6. To summarize the principal data given in Figs. 1, 2 and 3, and to show in addition 
the type of inactivation curve obtained by laking, immediately before assay, blood 
to which adrenaline has been added at zero time (see p. 246). 
the same extent in vivo. But in a later paper one of us will revert to this 
topic and will show, among other things, that the activity of cat's liver 
in respect of the adrenaline inactivating principle is not nearly so great 
as is that of the liver of some other mammals, including man. 
SUMMARY 
1. The methods used in studying the inactivation of adrenaline are 
described; all the experiments were made with cat's blood and cat's 
tissues and the adrenaline determinations made by blood pressure assay 
on spinal cats. 
2. In oxalatedbloodplasma andinblood serum inactivation of adrenal- 
hie proceeds slowly to completion ; itis more rapid in serum than in plasma. 
3. In oxalated or defibrinated whole blood inactivation is never 
complete; it proceeds to what it is convenient to call an equilibrium value 
beyond which no further inactivation can be demonstrated. 
4. Addition of tissue slices, or of concoctions of tissues, to blood and 
adrenaline leads to the complete disappearance of adrenaline activity 
from the blood. Many tissues show this activity to some extent but the 
most active, weight for weight, is liver. 
5. The adrenaline inactivating power of liver is not diminished by 
cyanide or cocaine: it is diminished by increased acidity of the medium and 
by the -withholding of oxygen; it is absent after the tissue has been boiled. 
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6. Further study of the inactivation of adrenaline by blood showed' 
that the equilibrium concentration varies with the initial concentration 
and that there is also some variation, for a given initial concentration, 
from sample to sample of blood. These last variations are probably due 
to variations in the cell /plasma or cell /serum ratios. 
7. The adrenaline value of an equilibrium mixture is represented 
exclusively by adrenaline in the plasma or serum, but a further amount 
of adrenaline is present in or on the cells of such a mixture, an amount 
which ordinarily is incapable of manifesting its presence by an action 
on the test animal. 
8. This additional adrenaline is in reversible association with the cells 
and can be recovered in maximum amount by laking the separated cells 
or the equilibrium mixture, or, in lesser amount, by placing separated 
equilibrium cells in fresh plasma or serum or Locke solution. Over 80 p.c. 
of the original adrenaline (20 -40y) added to blood is recoverable by 
laking an equilibrium mixture. 
9. The total adrenaline recoverable from blood seems to be inde- 
pendent of the integrity of the cells. 
10. Whether the association of adrenaline with the cells is one of 
simple adsorption, or of passage of adrenaline within the cells, or both, 
is not clear. Nor is it clear whether the 20 p.c. of original adrenaline 
irrecoverable from such a laked equilibrium mixture is irrecoverable 
because it is destroyed, or is combined in some way with some constituent 
of the blood, or is held inactive in the same way as the recoverable cell 
adrenaline but in a manner which renders its association irreversible 
under the conditions of our experiments. 
The expenses of this work have been partly met by a grant to one of us (W. A. B.) 
from the Government Grant Committee of the Royal Society. 
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On the inactivation of adrenaline by mammalian liver in vitro. 
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On the inactivation of adrenaline by mammalian liver in vitro. 
By W. A. BAIN and SYLVIA DICKINSON. (From the Pharmacological 
Laboratory, University of Leeds) 
A method has already been described for following the course of in- 
activation of adrenaline in vitro [Bain et al. 1937]. In the experiments 
here reported the inactivating power of different samples of liver, and of 
samples from different species, is compared. The technique used was the 
same as in the previous experiments except that the amount of liver used 
was less (1 g. per 5 ml. instead of 1 g. per ml.). The experiments were 
carried out at body temperature: the medium was defibrinated cat's 
blood; and the initial concentration of adrenaline was 40y per ml. The 
results were recorded by plotting the amount of adrenaline left against 
the interval of time between its addition to the blood and liver and the 
taking of the sample. On an average, seven points were determined in 
each experiment. The results of forty -two experiments are summarized 
in Table I. 
TABLE I. Approximate mean times in minutes for 50,75 and 90 p.c. inactivation of adrenaline 
by livers of different species. Figures in round brackets are the shortest and longest 
times obtained. Figures in square brackets indicate number of experiments on each 
species. 
P.c. in- Guinea -pig Man Rat Cat Dog Mouse 
activation [7] [13] [7] [7] [4] [4] 
50 12 13 27 34 38 42 
(8-17) (10 -16) (24 -31) (21 -50) (30 -44) (28-48) 
75 26 26 53 75 80 79 
(15 -35) (22 -31) (49 -60) (55 -107) (67 -100) (53 -93) 
90 47 43 84 
(31 -61) (35 -50) (78 -96) - - 
It will be seen that the rate of inactivation effected by the liver is 
different for different species. There is some variation in the curves 
obtained from livers of individuals of the same species. But in the 
guinea -pig, rat, and a set of thirteen samples of human liver, the results 
lie between fairly well -defined limits about a mean curve, the mean curve 
being characteristic of the species. It seems possible, therefore, to establish 
for each of these animals a normal "adrenaline inactivation curve" of 
liver to which the curve for any given individual will approximate. Wide 
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deviation from the characteristic curve would suggest an abnormality 
in the adrenaline inactivating power of the tissue. 
In three human livers the adrenaline inactivating power was found 
to be diminished to such an extent, the average times for 50, 75 and 
90 p.c. inactivation being 24, 43 and 70 min. respectively. Two of the 
subjects suffered from arteriál hypertension of non -renal origin and the 
third had a diastolic pressure of 90 mm. Hg, but no other evidence of 
hypertension. On the other hand, the group of thirteen human subjects 
includes four cases of chronic nephritic hypertension, in each of which 
the adrenaline inactivation curve falls within normal limits. It thus seems 
possible that essential hypertension may be associated with a diminished 
adrenaline inactivating power of the tissues. 
If adrenaline is the transmitter of adrenergic vasoconstrictor nerve 
activity the raised arterial tension in essential hypertension, and perhaps 
also in malignant hypertension, may be due to a potentiation of the 
effects of normal vasoconstrictor nerve activity resulting from the 
delayed inactivation of the transmitter. We hope to deal with this 
question in detail later. 
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On Adrenaline and Noradrenaline Inactivation 
by Human Liver in vitro. 
From J. Physiol. 1952, 118, 13P. 
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On adrenaline and noradrenaline inactivation 
by human liver in vitro 
By W.A. Bain and Jean E. Batty. Department 
of Pharmacology, University of Leeds. 
Bain & Dickinson (1938) showed that, when liver slices 
from various mammals were incubated at 37 °C in blood 
with 4011g /ml. adrenaline, the rate of adrenaline 
inactivation varied with the species and was fastest 
in the guinea -pig and man, slowest in the cat, dog 
and mouse, and intermediate in the rat. 
In three out of sixteen human livers, however, 
the inactivation rate approximated to that of rat 
liver, and as two of the subjects had suffered from 
arterial hypertension of non -renal origin it was 
suggested that delayed inactivation of the trans- 
mitter might be responsible for such forms of raised 
blood pressure. 
We have now compared, by the same methods as 
before, the inactivation rates of adrenaline and of 
of noradrenaline by twenty -eight samples of human 
liver. An average of six points was determined for 
each drug in each experiment. The mean regressions 
for, all experiments are: 
adrenaline, In Y = lnyo - 0.04474t; noradrenaline, 
In Y = lnyo - 0.05655t; the difference between them 
is highly significant (P <0.001). The calculated 
mean half -inactivation times in minutes, and their 
1 
fiducial limits (P a 0.95), are: adrenaline, 
15.5 (13.8 - 17.7); noradrenaline, 12.25 (11.1 _ 13.7). 
Inactivation of both drugs is unaffected by 
cyanide but is inhibited by octyl alcohol, so the 
enzyme concerned is amine oxidase ( Blaschko, Richter 
& Schlossmann, 1937). 
Though some livers seem to inactivate both drugs 
so slowly as to belong to a separate category - as in 
the previous observations with adrenaline - this is 
difficult to prove; and the clinical data available 
give no help one way or the other. 
It is clear, however, that the hypothesis 
concerning delayed inactivation of adrenaline as a 
possible factor in causing certain forms of high 
blood pressure can now be extended to include nor - 
adrenaline. But any rigorous test of the validity 
of this hypothesis will require many more experiments 
than we have been able to do, and clinical information 
about the cases of a much more critical kind than we 
have been able to get. 
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